Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 498. Отображено 100.
26-01-2012 дата публикации

Natural oil polyols in elastomers for tires

Номер: US20120018066A1
Автор: Kandathil E. Verghese, Rui Xie, Syed A. Shah
Принадлежит: Dow Global Technologies LLC

Prepolymers having active NCO groups are disclosed. The prepolymers are the reaction product of at least one polyisocyanate and a polyhydric component which comprises at least one dimer fatty derivative diol or diamine that is a natural oil based polyol or polyamine which includes the derivative of at least one dimer fatty acid. Polyurethane and polyurea elastomer obtained from the prepolymers are also disclosed. Also disclosed are methods of manufacturing polyurethane or polyurea treaded tires.

Подробнее
Номер записи: 1
08-03-2012 дата публикации

DRY POWDER COMPOUND FORMULATIONS AND USES THEREOF

Номер: US20120059025A1
Автор: Ofslager Christian, SHAH Syed M.
Принадлежит: Wyeth

The present invention provides lyophilized formulations comprising methylnaltrexone, and processes for preparation of provided formulations. Additionally provided are compositions and products containing the methylnaltrexone formulation, as well as methods for producing formulations, compositions and products. Provided formulations as well as compositions and products containing methylnaltrexone formulations are useful for preventing, treating delaying, diminishing or reducing the severity and/or incidence of side effects resulting from administration of analgesic opioids. 1. An amorphous dry powder formulation consisting essentially of methylnaltrexone , or a pharmaceutically acceptable salt thereof , and a filler.2. The formulation of claim 1 , wherein the methylnaltrexone is methylnaltrexone bromide.3. The formulation of claim 1 , wherein the filler is selected from the group consisting of a lactose claim 1 , mannitol claim 1 , and dextran.4. The formulation of claim 3 , wherein the filler is a lactose and the methylnaltrexone is methylnaltrexone bromide.5. The formulation of claim 4 , wherein the lactose is lactose monohydrate.6. The formulation of claim 1 , consisting essentially of:about 5 to about 500 mg of methylnaltrexone bromide; andlactose monohydrate.7. The formulation of claim 1 , wherein the methylnaltrexone and filler are present in approximately equal amounts by weight.8. The formulation of claim 1 , wherein the methylnaltrexone and filler are present in a ratio within the range of about 1:1 to about 1:5 by weight.9. A solution consisting essentially of water and the formulation of .10. The solution of claim 9 , wherein the lactose is lactose monohydrate.11. The solution of claim 10 , wherein the methylnaltrexone bromide and lactose monohydrate are present in approximately equal amounts by weight.12. The solution of claim 11 , wherein methylnaltrexone bromide is present in a concentration of about 0.5 mg/mL to about 25 mg/mL.13. A method of producing ...

Подробнее
Номер записи: 2
22-03-2012 дата публикации

ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE

Номер: US20120070495A1
Автор: AL SHAREFFI Kadum A., COHEN Jonathan Marc, DIORIO Christopher Richard, EHRNSPERGER Eric C., MENG Xu, SHAH Syed M.
Принадлежит: WYETH LLC

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. 2. The salt according to claim 1 , wherein the pharmaceutically acceptable excipient has a pKof 3 or less.3. The salt according to claims 1 , wherein the pharmaceutically acceptable excipient comprises a sulfate (—OSO) group.43. The salt according to anyone of - claims 1 , wherein the pharmaceutically acceptable excipient comprises a saturated or unsaturated claims 1 , branched or unbranched claims 1 , cyclic or acyclic Caliphatic group that is optionally substituted.5. The salt according to claim 1 , wherein the pharmaceutically acceptable excipient comprises a saturated claim 1 , unbranched claim 1 , acyclic claim 1 , unsubstituted Calkyl group.6. (canceled)7. (canceled)8. The salt according to claim 1 , wherein A is dodecyl sulfate.9. A pharmaceutical composition for oral administration comprising the salt according to .10. A pharmaceutical composition for oral administration comprising a solid dosage of methylnaltrexone or a pharmaceutically acceptable salt thereof claim 1 , and an amphiphilic pharmaceutically acceptable excipient.11. The pharmaceutical composition of claim 10 , wherein the methylnaltrexone or a pharmaceutically acceptable salt thereof claim 10 , and the amphiphilic pharmaceutically acceptable excipient form an ion pair when dissolved in solution.12. The pharmaceutical composition of claim 11 , wherein the ion pair is formed when the methylnaltrexone or a pharmaceutically acceptable salt thereof and the amphiphilic pharmaceutically acceptable excipient are dissolved in solution at a pH of greater than about 1 and less than about 4.13. The pharmaceutical composition of claim 12 , further comprising a disintegrant.14. The pharmaceutical composition of claim 10 , wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° ...

Подробнее
Номер записи: 3
02-08-2012 дата публикации

CONTROLLED-RELEASE MELATONIN COMPOSITIONS AND RELATED METHODS

Номер: US20120195968A1
Автор: HASSAN DANIEL, SHAH Syed M.
Принадлежит:

This disclosure relates to controlled-release melatonin compositions and related methods. In one embodiment, a controlled-release medicament composition comprises melatonin dispersed in a controlled melatonin release portion comprising a polymer matrix, the polymer matrix adapted to encapsulate the melatonin in a melatonin solubility enhancing pH environment and to maintain the melatonin solubility enhancing pH environment when the composition is located in a melatonin solubility diminishing pH environment for allowing an effective amount of melatonin to be released into the melatonin solubility diminishing pH environment. 1. A controlled-release medicament composition comprising melatonin dispersed in a controlled melatonin release portion comprising a polymer matrix , the polymer matrix adapted to encapsulate the melatonin in a melatonin solubility enhancing pH environment and to maintain the melatonin solubility enhancing pH environment when the composition is located in a melatonin solubility diminishing pH environment for allowing an effective amount of melatonin to be released into the melatonin solubility diminishing pH environment.2. The composition of claim 1 , wherein the polymer matrix forms a hydrogel.3. The composition of claim 1 , wherein the melatonin solubility enhancing pH environment is an acidic pH environment.4. The composition of claim 3 , wherein the pH is between approximately 2-4.5. The composition of claim 3 , wherein the acidic pH environment is provided by an acidic substance in the polymer matrix.6. The composition of claim 5 , wherein the acidic substance is at least one of citric acid claim 5 , succinic acid claim 5 , tartaric acid claim 5 , phosphoric acid claim 5 , or hydrochloric acid.7. The composition of claim 5 , wherein the acidic substance is citric acid.8. The composition of claim 1 , wherein the controlled melatonin release portion further comprises polyethylene glycol.9. The composition of claim 8 , wherein the polyethylene ...

Подробнее
Номер записи: 4
01-11-2012 дата публикации

TIGECYCLINE FORMULATIONS

Номер: US20120277197A1
Автор: Bazhina Nataliya, Chanana Gurmukh Das, Fawzi Mahdi Bakir, Ofslager Christian Luther, Shah Syed Muzafar
Принадлежит: Wyeth

The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state at about 22° C. or in an unfrozen state at about 22° C. has a pH in the range of from 4.0 to 5.5. Preferably, the formulation is suitable for storage at or below about −20° C. over a period of at least about 2 months, preferably 6 months, more preferably 26 months. Alternatively, the formulation is suitable for storage at about 22° C. over a period of about 24 hours. 1. A frozen pharmaceutical formulation suitable for administration to a subject parenterally , comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose , dextrose , glucose , mannose , sucrose , ribose , xylose and a combination thereof , wherein the formulation in a pre-frozen state at about 22° C. or in an unfrozen state at about 22° C. has a pH in the range of from 4.0 to 5.5 , said frozen pharmaceutical formulation having a tigecycline epimer concentration in the formulation at or below about 3% of the concentration of tigecycline.2. The formulation of claim 1 , wherein the agent is selected from the group consisting of lactose claim 1 , dextrose claim 1 , glucose claim 1 , mannose claim 1 , and a combination thereof.34-. (canceled)5. The formulation of claim 1 , wherein the therapeutically effective amount of tigecycline is about 150 mg.6. The formulation of claim 1 , wherein tigecycline is in a concentration within the range of about 0.1 mg/ml to about 2.0 mg/ml.7. The formulation of claim 6 , wherein tigecycline is in a concentration within the range of about 0.5 to about 1.5 mg/ml.8. The formulation of claim 1 , wherein the pH is from 4.5 to 5.1.9. The formulation of claim 1 ...

Подробнее
Номер записи: 5
13-12-2012 дата публикации

Multiparticulate l-carnitine compositions and related methods

Номер: US20120315326A1
Автор: Noreen HASSAN, Syed Shah
Принадлежит: Hassan Noreen, Shah Syed

Enteric coated multiparticulate compositions that use a L-carnitine compound an active ingredient are disclosed. The multiparticulates have spheroidal core comprising a L-carnitine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions.

Подробнее
Номер записи: 6
13-12-2012 дата публикации

MULTIPARTICULATE 5-HTP COMPOSITIONS AND RELATED METHODS

Номер: US20120315337A1
Автор: Hassan Noreen, Shah Syed
Принадлежит:

Enteric coated multiparticulate compositions that use 5-HTP as an active ingredient are disclosed. The multiparticulates have a spheroidal core comprising 5-HTP, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methylcellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions. 1. A composition comprising a plurality of independently dispersible particulates , each independently dispersible particulate comprising:a spheroidal core comprising about 70%-90% w/w 5-Hydroxytryptophan, about 15%-25% w/w microcrystalline cellulose, and about 0.5%-1.5% w/w hydroxypropyl methylcellulose;a sub-coat on the spheroidal core, the subcoat comprising hydroxypropyl methyl cellulose present in an amount of about 2%-4% w/w of the independently dispersible particulates; andan enteric coat on the sub-coated spheroidal core, the enteric coat being about 5%-15% w/w of the independently dispersible particulates;wherein the average diameter of the independently dispersible particulates is about 0.1-3 mm.2. The composition of claim 1 , wherein the spheroidal core further comprises about 0.005% to 1.5% w/w melatonin.3. The composition of claim 2 , wherein the spheroidal core further comprises about 2.0% to 7.0% w/w of PEG8000 and about 3.0% to 40% w/w of citric acid.4. The composition of claim 1 , wherein the spheroidal core further comprises an outer coating having about 0.005% to 1.5% w/w melatonin.5. The composition of claim 1 , wherein the enteric coat is selected from methacrylic acid co-polymer claim 1 , cellulose acetate phthalate claim 1 , polyvinyl acetate phthalate claim 1 , or a combination thereof.6. The composition of claim 1 , wherein the enteric coat comprises a polymeric material that forms a film around the core and a pore former ...

Подробнее
Номер записи: 7
13-12-2012 дата публикации

Peripheral Opioid Receptor Antagonists and Uses Thereof

Номер: US20120316191A1
Автор: Bazhina Nataliya, Donato, Fabian Steven R., III George Joseph, Lokhnauth John, Megati Sreenivasulu, Melucci Charles, Ofslager Christian, Patel Niketa, Radebaugh Galen, SHAH Syed M., Szeliga Jan, Zhang Huyi, Zhu Tianmin
Принадлежит: Wyeth

The present invention provides a compound of formula I: 2. The method of claim 1 , wherein the gastrointestinal disorder is constipation.3. The method of claim 2 , wherein the constipation is opioid-induced.4. The method of claim 1 , wherein the compound is provided in a solution.6. The method of claim 5 , wherein the compound is provided in solution.7. The method of claim 5 , wherein the gastrointestinal disorder is constipation.8. The method of claim 7 , wherein the constipation is opioid-induced.9. The method of claim 1 , wherein the subject is receiving opioids chronically.10. The method of claim 9 , wherein the subject is a cancer patient.11. The method of claim 1 , wherein the packaged composition is selected from the group consisting of a syringe claim 1 , a vial claim 1 , a sachet and an ampoule.12. The method of claim 1 , wherein the packaged composition is a syringe.13. The method of claim 1 , wherein the compound is in the form of a tablet claim 1 , a capsule claim 1 , a powder claim 1 , a solution claim 1 , a suspension claim 1 , an emulsion claim 1 , a granule claim 1 , and a suppository.16. The method of claim 6 , wherein the compound is administered by injection or infusion.17. The method of claim 16 , wherein the compound is administered by subcutaneous injection.18. The method of claim 1 , wherein the subject is receiving an opioid at a morphine equivalent dose of between about 30 and 100 oral mg/day of methadone.19. The method of claim 1 , wherein the tungsten is present in an amount of less than 50 parts per billion.20. The method of claim 1 , wherein the tungsten is present in an amount of less than 12 parts per billion.21. The method of claim 6 , wherein the solution further comprises edetate calcium disodium and glycine hydrochloride.22. The method of claim 6 , wherein the solution comprises about 8 mg of compound in about 0.4 mL water.24. The method of claim 6 , wherein the solution comprises about 12 mg of compound in about 0.6 mL water.26. ...

Подробнее
Номер записи: 8
10-01-2013 дата публикации

PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF

Номер: US20130011929A1
Автор: Bazhina Nataliya, Donato, Fabian Steven R., III George Joseph, Lokhnauth John, Megati Sreenivasulu, Melucci Charles, Ofslager Christian, Patel Niketa, Radebaugh Galen, SHAH Syed M., Szeliga Jan, Zhang Huyi, Zhu Tianmin
Принадлежит: Wyeth

The present invention provides a compound of formula I: 2. The compound according to claim 1 , wherein X is the anion of a suitable Brønsted acid.3. The compound according to claim 2 , wherein the Brønsted acid is a hydrogen halide claim 2 , a carboxylic acid claim 2 , a sulfonic acid claim 2 , a sulfuric acid claim 2 , or a phosphoric acid.4. The compound according to claim 2 , wherein X is chloride claim 2 , bromide claim 2 , iodide claim 2 , fluoride claim 2 , sulfate claim 2 , bisulfate claim 2 , tartrate claim 2 , nitrate claim 2 , citrate claim 2 , bitartrate claim 2 , carbonate claim 2 , phosphate claim 2 , malate claim 2 , maleate claim 2 , fumarate claim 2 , sulfonate claim 2 , methylsulfonate claim 2 , formate claim 2 , carboxylate claim 2 , methylsulfate claim 2 , trifluoroacetate claim 2 , or succinate.5. The compound according to claim 4 , wherein X is bromide.6. The compound according to claim 1 , wherein Ris Caliphatic and Ris lower alkyl.7. The compound according to claim 6 , wherein Ris a (cycloalkyl)alkyl group or alkenyl group.8. The compound according to claim 7 , wherein Ris cyclopropyl methyl or allyl and Ris methyl.12. A method comprising the steps of:(a) providing a sample of (R)—N-methylnaltrexone bromide;(b) performing an analysis of the sample of (R)—N-methylnaltrexone bromide; and(c) determining the amount of compound II-1 in the sample of (R)—N-methylnaltrexone bromide.13. The method according to claim 12 , wherein step (c) further comprises the step of determining the amount of compound IV-1 in the sample of (R)—N-methylnaltrexone bromide.14. The method according to claim 13 , wherein step (c) comprises determining that the amount of compound II-1 and compound IV-1 in the sample of (R)—N-methylnaltrexone bromide is less than about 60 ppm claim 13 , about 10 ppm claim 13 , about 5 ppm claim 13 , about 3.3 ppm claim 13 , about 2.5 ppm claim 13 , or about 1 ppm total.15. The method according to claim 13 , wherein step (c) comprises ...

Подробнее
Номер записи: 9
06-06-2013 дата публикации

METHOD OF ENHANCING THE SHELF STABILITY OF PROBIOTICS

Номер: US20130142907A1
Автор: Hong Liang, Lichtenwald Kathy L., Madduri Krishna, Shah Syed A., Tucker Christopher J., Woelfle Caroline
Принадлежит: Dow Global Technologies LLC

Described are methods of providing a shelf-stable probiotic-containing food or beverage, comprising forming a semi-permeable microsphere, said microsphere comprising a probiotic, a high molecular weight polymer, and an effective amount of bacteriostatic agent. 1. A method of providing a shelf-stable probiotic-containing food or beverage , comprising:forming a semi-permeable microsphere comprising a probiotic, a high molecular weight polymer, and an effective amount of bacteriostatic agent,introducing the microsphere into the relatively high humidity food or beverage, wherein said relatively high humidity food has a residual moisture level greater than 10% water, andstoring said food or beverage before consumption without refrigeration for at least 6 weeks.2. The method of claim 1 , wherein the probiotic experiences a reduction in population of 1 log cfu or less.3. The method of claim 1 , wherein the high molecular weight polymer is ethylcellulose.4. The method of claim 1 , wherein the high molecular weight polymer is alginate.5. The method of claim 1 , wherein the microsphere is in a beverage.6. The method of claim 5 , wherein the beverage has a pH less than 5.7. The method of claim 1 , wherein the microsphere is in a relatively high humidity food that has a residual moisture level greater than 20% water claim 1 , preferably greater than 30% water claim 1 , preferably greater than 40% water claim 1 , more preferably greater than 50% water.8. The method of claim 1 , wherein the microsphere is in a relatively high humidity food that has a water activity greater than 0.6 claim 1 , preferably greater than 0.7 claim 1 , preferably greater than 0.8 water claim 1 , more preferably greater than 0.9.9. The method of claim 1 , wherein the relatively high humidity food includes pet food claim 1 , snack foods claim 1 , health bars claim 1 , and non-cooked pre-packaged mixes.10. The method of claim 1 , wherein the microsphere has a multilayer composition claim 1 , provided the ...

Подробнее
Номер записи: 10
12-12-2013 дата публикации

Oral formulations and lipophilic salts of methylnaltrexone

Номер: US20130330407A1
Автор: Christopher Richard Diorio, Eric C. Ehrnsperger, Jonathan Marc Cohen, Kadum A. Al Shareffi, Syed M. Shah, Xu Meng
Принадлежит: WYETH LLC

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

Подробнее
Номер записи: 11
02-01-2014 дата публикации

CRYSTAL FORMS OF (R)-N-METHYLNALTREXONE BROMIDE AND USES THEREOF

Номер: US20140004188A1
Автор: AL SHAREFFI Kadum A., Boyd Thomas A., Perez Julio, SHAH Syed M., Smolenskaya Valeriya N.
Принадлежит:

The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist. 2. The compound according to claim 1 , characterized in that the compound has one or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9 claim 1 , 8.18 claim 1 , 20.3 claim 1 , 21.44 claim 1 , 24.11 claim 1 , and 25.12 degrees 2-theta.34-. (canceled)5. The compound according to claim 1 , characterized in that the compound has substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 7.9 claim 1 , 8.18 claim 1 , 10.64 claim 1 , 11.57 claim 1 , 12.68 claim 1 , 13.44 claim 1 , 13.89 claim 1 , 14.38 claim 1 , 15.42 claim 1 , 16.01 claim 1 , 16.39 claim 1 , 17.18 claim 1 , 19.89 claim 1 , 20.79 claim 1 , 21.44 claim 1 , 21.9 claim 1 , 23.35 claim 1 , 24.49 claim 1 , 24.87 claim 1 , 25.53 claim 1 , and 29.17 degrees 2-theta.6. (canceled)7. The compound according to claim 1 , characterized in that the compound has an X-ray powder diffraction pattern substantially similar to that depicted in .9. The compound according to claim 8 , characterized in that the compound has one or more peaks in its X-ray powder diffraction pattern selected from those at about 7.66 claim 8 , 8.42 claim 8 , 14.79 claim 8 , and 21.06 degrees 2-theta.1011-. (canceled)12. The compound according to claim 8 , characterized in that the compound has substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 7.66 claim 8 , 8.42 claim 8 , 12.85 claim 8 , 13.48 claim 8 , 16.11 claim 8 , 17.53 claim 8 , 18.67 claim 8 , 19.61 claim 8 , 21.06 claim 8 , 21.79 claim 8 , 22.07 claim 8 , 23.25 claim 8 , 24.53 claim 8 , and 26.23 degrees 2-theta.13. (canceled)14. The compound according to claim 8 , characterized in that the compound has an X-ray powder diffraction pattern substantially similar to that depicted in .16. The compound according to claim 15 , ...

Подробнее
Номер записи: 12
02-01-2014 дата публикации

COATED DRUG SPHEROIDS AND USES THEREOF FOR ELIMINATING OR REDUCING CONDITIONS SUCH AS EMESIS AND DIARRHEA

Номер: US20140004203A1
Автор: DIORIO Christopher Richard, Murphy Eugene, Rao Sripriya Venkata Ramana, Shah Syed Muzafar, Vencl-Joncic Maja
Принадлежит: WYETH LLC

The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors. 1. A pharmaceutically acceptable composition of (i) spheroid particles comprising: (a) 30-70 weight percent of (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide or a pharmaceutically acceptable salt thereof; (b) 20-30 weight percent of one or more fillers; and (c) 5-15 weight percent of one or more wetting agents , said spheroid particles comprising 70-83 weight percent of the total composition; (ii) a sub-coating applied to said spheroid particles further comprising 1-4 weight percent of one or more pharmaceutically acceptable cellulose based polymers and (iii) 16-30 weight percent of one or more pharmaceutically acceptable polymers as an enteric coating applied to said sub-coating , said coating components (ii) and (iii) comprising 17-30 weight percent of the total composition.2. A pharmaceutically acceptable composition of (i) spheroid particles comprising: (a) 30-70 weight percent of (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide maleate; (b) 20-30 weight percent of microcrystalline cellulose; and (c) 5-15 weight percent of a polysorbate , said spheroid particles comprising 70-84 weight percent of the total composition; (ii) a sub-coating applied to said spheroid particles further comprising 1-4 weight percent of hydroxypropylcellulose and (iii) 16-30 weight percent of a methacrylic acid polymer as an enteric coating applied to said sub-coating , said coating components (ii) and (iii) comprising 16-30 weight percent of the total composition.3. The composition according to claim 2 , wherein the weight percent of (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3 ...

Подробнее
Номер записи: 13
16-01-2014 дата публикации

MULTIPARTICULATE L-MENTHOL FORMULATIONS AND RELATED METHODS

Номер: US20140017324A1
Автор: HASSAN DANIEL, HASSAN FRED, HASSAN SARAH, Shah Syed
Принадлежит: ZX PHARMA, LLC

An L-menthol-containing multiparticulate formulation includes a plurality of individual enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. The enteric coated cores are effective to release at least about 35% of the L-menthol within about two hours, and at least about 80% of the L-menthol within about eight hours after being placed in an environment having a pH of 5 to 8. The L-menthol multiparticulate formulation can be used to treat gastrointestinal disorders. 1. A multiparticulate formulation comprising a plurality of individual enteric coated cores containing L-menthol from an at least 80% pure L-menthol source , the enteric coated cores being effective to release at least about 35% of the L-menthol within about two hours , and at least about 80% of the L-menthol within about eight hours after being placed in an environment having a pH of between 5 to 8.2. The multiparticulate formulation of claim 1 , wherein the enteric coated cores further comprise a proton pump inhibitor.3. The multiparticulate formulation of claim 1 , wherein the enteric coated cores further comprise an anti-inflammatory.4. The multiparticulate formulation of claim 1 , wherein the enteric coated cores further comprise an immune suppressor.5. The multiparticulate formulation of claim 1 , further comprising a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings.6. The multiparticulate formulation of claim 5 , wherein the continuous proteinaceous subcoating comprises a gelatin film adhered to the core.7. The multiparticulate formulation of claim 5 , wherein the continuous proteinaceous subcoating comprises a dried proteinaceous gel.8. The multiparticulate formulation of claim 5 , wherein the continuous proteinaceous subcoating is adapted to prevent the L-menthol from mixing with the enteric coating.9. The multiparticulate formulation of claim 5 , wherein the enteric ...

Подробнее
Номер записи: 14
16-01-2014 дата публикации

ENTERIC COATED MULTIPARTICULATE CONTROLLED RELEASE PEPPERMINT OIL COMPOSITION AND RELATED METHODS

Номер: US20140017325A1
Автор: HASSAN DANIEL, HASSAN FRED, Shah Syed
Принадлежит: ZX PHARMA, LLC

A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders. 1. A multiparticulate composition comprising a plurality of individual enteric coated cores , the cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel.2. The multiparticulate composition of claim 1 , further comprising a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings.3. The multiparticulate composition of claim 2 , wherein the continuous proteinaceous subcoating comprises a gelatin film adhered to the core.4. The multiparticulate composition of claim 2 , wherein the continuous proteinaceous subcoating comprises a dried proteinaceous gel.5. The multiparticulate composition of claim 2 , wherein the continuous proteinaceous subcoating is adapted to prevent the peppermint oil from mixing with the enteric coating.6. The multiparticulate composition of claim 2 , wherein the enteric coating has a glass transition temperature higher than a standard boiling point of the peppermint oil.7. The multiparticulate composition of claim 1 , wherein the enteric coated cores release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HCl solution and claim 1 , subsequently claim 1 , no less than about 85% of the peppermint oil within about eight hours of being placed in a substantially neutral pH environment.8. The multiparticulate composition of claim 1 , wherein the enteric coated cores are spheroidal and not more than 3 mm in diameter.9. A multiparticulate composition comprising ...

Подробнее
Номер записи: 15
16-01-2014 дата публикации

LOCKABLE MATING CONNECTOR

Номер: US20140017928A1
Автор: Collier Donald Wayne, Shah Syed Sarwar
Принадлежит: Molex Incorporated

A connector includes a housing and a locking member slidably mounted on the housing for movement between a mateable position and a locked position. First and second locking components interact to lock the locking sleeve in a locked position. Each of a plurality of deflectable spring arms includes a latching component for latching to a mating connector. At the locked position, each of the spring arms is secured in a latched position. 1. An electrical connector for interconnecting to a mating electrical connector along a mating axis , comprising:a body;a locking sleeve, the locking sleeve being slidably mounted on the body for movement between a mateable position and a locked position, and comprising a first locking component;a conductive contact, the conductive contact being disposed within the body for mating with a first conductive contact of the mating electrical connector;a generally cylindrical conductive outer contact, the conductive outer contact mating with a second conductive contact of the mating electrical connector and being generally coaxial with the conductive contact;a plurality of deflectable spring arms, each spring arm comprising a latching component, the latching component latching the electrical connector to the mating electrical connector; anda second locking component, the second locking component engaging the first locking component upon positioning the locking sleeve at the locked position to secure the locking sleeve at the locked position; at the locked position, deflection of the spring arms is prevented by the locking sleeve; and', 'the first locking component engages the second locking component to secure the locking sleeve relative to the spring arms., 'wherein2. The electrical connector of claim 1 , wherein the body is electrically conductive.3. The electrical connector of claim 2 , wherein the body is electrically connected to the conductive outer contact.4. The electrical connector of claim 1 , wherein the second locking component is ...

Подробнее
Номер записи: 16
06-03-2014 дата публикации

MULTIPARTICULATE L-MENTHOL FORMULATIONS AND RELATED METHODS

Номер: US20140065230A1
Автор: HASSAN DANIEL, HASSAN SARAH, Shah Syed
Принадлежит: ZX PHARMA, LLC

A multiparticulate formulation includes a plurality of individual spheroidal enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. A subcoat is beneath the enteric coat. The enteric coated cores have a diameter of not more than 3 mm. The multiparticulate formulation may be used to treat gastrointestinal disorders, such as irritable bowel syndrome. 1. A multiparticulate formulation comprising a plurality of individual spheroidal enteric coated cores having a diameter of not more than 3 mm , the enteric coated cores comprising L-menthol from an at least 80% pure L-menthol source and a subcoat beneath the enteric coat.2. The multiparticulate formulation of claim 1 , wherein the enteric coated cores are effective to release at least 80% of the L-menthol within about 2 hours of being placed in an intestinal pH environment.3. The multiparticulate formulation of claim 1 , wherein the L-menthol source is crystalline L-menthol.4. The multiparticulate formulation of claim 1 , wherein the cores further comprise a solubilizing agent effective for solubilizing L-menthol.5. The multiparticulate formulation of claim 1 , wherein the cores further comprise an antioxidant effective for preventing the L-menthol from oxidizing.6. The multiparticulate formulation of claim 5 , wherein the antioxidant is ascorbic acid.7. The multiparticulate formulation of claim 1 , wherein the cores comprise about 30% to about 70% w/w L-menthol.8. The multiparticulate formulation of claim 1 , wherein the enteric coated cores are effective to release no more than about 10% of the L-menthol within about 2 hours of being placed in a 0.1 N HCl solution and claim 1 , subsequently claim 1 , no less than about 85% of the L-menthol within about two hours of being placed in a substantially neutral pH environment.9. The multiparticulate formulation of claim 1 , wherein the enteric coated cores are combined in a pharmaceutical dosage form that can be orally administered to a patient. ...

Подробнее
Номер записи: 17
20-03-2014 дата публикации

PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF

Номер: US20140080854A1
Автор: Bazhina Nataliya, Donato, Fabian Steven R., III George Joseph, Lokhnauth John, Megati Sreenivasulu, Melucci Charles, Ofslager Christian, Patel Niketa, Radebaugh Galen, SHAH Syed M., Szeliga Jan, Zhang Huyi, Zhu Tianmin
Принадлежит: Wyeth

The present invention provides a compound of formula I: 146-. (canceled)49. The packaged composition of claim 47 , wherein the packaged composition comprises a syringe claim 47 , a vial claim 47 , a sachet or an ampoule.51. The packaged composition of claim 50 , wherein the packaged composition comprises a syringe claim 50 , a vial claim 50 , a sachet or an ampoule.54. The packaged composition according to claim 53 , wherein the liquid composition further comprises 2.6 mg sodium chloride claim 53 , 0.16 mg edetate calcium disodium claim 53 , and 0.12 mg glycine hydrochloride.56. The packaged composition according to claim 55 , wherein the liquid composition further comprises 3.9 mg sodium chloride claim 55 , 0.24 mg edetate calcium disodium claim 55 , and 0.18 mg glycine hydrochloride.58. The method of claim 57 , wherein the packaged composition comprises a syringe claim 57 , a vial claim 57 , a sachet or an ampoule.59. The method according to claim 57 , wherein the subject is suffering from opioid induced constipation.60. The method according to claim 57 , wherein the tungsten is present in an amount of less than 50 parts per billion.61. The method according to claim 57 , wherein the tungsten is present in an amount of less than 12 parts per billion.62. The method according to claim 57 , wherein the liquid composition further comprises edetate calcium disodium and glycine hydrochloride.63. The packaged composition of claim 50 , wherein the packaged composition is substantially free of tungsten.64. The packaged composition of claim 47 , wherein the liquid composition comprises less than about 187 ppm claim 47 , 185 ppm claim 47 , 150 ppm claim 47 , 125 ppm claim 47 , 100 ppm or 25 ppm of the compound of formula II.65. The packaged composition of claim 48 , wherein the liquid composition comprises less than about 187 ppm claim 48 , 185 ppm claim 48 , 150 ppm claim 48 , 125 ppm claim 48 , 100 ppm or 25 ppm total of the compound of formula II and the compound of ...

Подробнее
Номер записи: 18
06-01-2022 дата публикации

ADHESIVELY ATTACHED EYE MASKS

Номер: US20220000197A1
Автор: Shah Syed
Принадлежит:

An adhesively attached eye mask includes a transparent or semi-transparent plastic eyepiece for positioning over a user's eyes and an integral elongated transparent plastic temple or tab extending rearward from each side edge of the eyepiece for contacting the sides of a user's face. A peripheral edge of the eyepiece can include an adhesive. A face mask can be connected to a lower edge of the eye mask for covering the user's nose and mouth. A peripheral edge of the face mask can include an adhesive. A flexible loop or band can be positioned at each side of the face mask. 1. An adhesively attached eye mask , comprising:a transparent eyepiece having a peripheral edge including an adhesive material; andan elongated temple attached to respective side edges of the eyepiece, each temple including an adhesive material.2. The adhesively attached eye mask according to claim 1 , wherein an inner peripheral surface of the eyepiece and an inner surface of each elongated temple is coated with the adhesive material.3. The adhesively attached eye mask according to claim 1 , wherein the adhesive material is provided on an adhesive strip positioned along a peripheral edge of the eyepiece claim 1 , with a portion of the strip adhered to the peripheral edge of the eyepiece and a remaining portion of the strip extending beyond the edge of the eyepiece.4. The adhesively attached eye mask according to claim 1 , wherein each of the temples includes an ear loop at a distal end thereof.5. The adhesively attached eye mask according to claim 1 , further comprising:a face mask extending from a bottom edge of said eyepiece, the face mask having a body including at least one layer of flexible sheet material, the body configured for covering a user's nose and mouth.6. The adhesively attached eye mask according to claim 5 , wherein an adhesive is provided along a peripheral edge of the mask body.7. The adhesively attached eye mask according to claim 6 , wherein an inner surface of the peripheral ...

Подробнее
Номер записи: 19
07-01-2016 дата публикации

Multiparticulate L-Menthol Formulations and Related Methods

Номер: US20160000728A1
Автор: HASSAN DANIEL, SHAH Syed M.
Принадлежит:

An L-menthol pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core and an enteric coating over the core. The core includes an L-menthol source that is at least 80% pure L-menthol. The dosage form may be used to treat gastrointestinal disorders, such as irritable bowel syndrome.

Подробнее
Номер записи: 20
02-01-2020 дата публикации

CELLULOSE ACETATE FIBERS IN NONWOVEN FABRICS

Номер: US20200002847A1
Автор: Appling Yancey, Gaynor Scott Gregory, Ghosh Koushik, Hassan Mohammad Abouelreesh, Izallalen Mounir, Posa James M., Qin Guo Wei, Shah Syed Ali, Spruell Jason Michael, Steach Jeremy Kenneth
Принадлежит: EASTMAN CHEMICAL COMPANY

Staple fibers and filament yarns formed from cellulose esters, such as cellulose acetate, are described herein, along with methods of making the fibers and their use in nonwoven fabrics and articles. The filament yarns and fibers described herein may be coated with at least one finish and, in some cases, may be coated with two or more finishes selected to enhance the properties of the fibers. Staple fibers as described herein may be used to produce nonwoven webs that are strong, soft, absorbent, and biodegradable, and may be used in wet or dry nonwoven articles for a variety personal care, medical, industrial, and commercial applications. 1. A staple fiber formed from cellulose acetate , wherein said fiber is at least partially coated with at least one finish , wherein said fiber has a denier per filament of less than about 3.0 and a crimp frequency of less than 22 crimps per inch (CPI) , and wherein a plurality of said fibers exhibit a fiber-to-fiber staple pad coefficient of friction of not more than about 0.70.2. The staple fiber of claim 1 , wherein said fiber has a static half-life of not more than about 12 minutes and wherein a plurality of said fibers exhibit a fiber-to-fiber staple pad coefficient of friction of at least about 0.1.3. The staple fiber of claim 1 , wherein a plurality of said fibers exhibit a fiber-to-fiber staple pad coefficient of friction of at least about 0.1 and wherein said fiber has a surface resistivity claim 1 , expressed as log R claim 1 , of not more than about 11.4. The staple fiber of claim 1 , wherein said fiber is at least partially coated with a spinning finish and a top-coat finish claim 1 , wherein said spinning finish is present on said fiber in an amount of at least about 0.5% FOY and wherein said top-coat finish is present on said fiber in an amount of not more than about 0.5% FOY claim 1 , and wherein each of said spinning finish and said top-coat finish have been applied prior to cutting a filament yarn to form said ...

Подробнее
Номер записи: 21
02-01-2020 дата публикации

CELLULOSE ACETATE FIBERS IN NONWOVEN FABRICS

Номер: US20200002858A1
Автор: Appling Yancey, Gaynor Scott Gregory, Ghosh Koushik, Hassan Mohammad Abouelreesh, Izallalen Mounir, Posa James M., Qin Guo Wei, Shah Syed Ali, Spruell Jason Michael, Steach Jeremy Kenneth
Принадлежит: EASTMAN CHEMICAL COMPANY

Staple fibers and filament yarns formed from cellulose esters, such as cellulose acetate, are described herein, along with methods of making the fibers and their use in nonwoven fabrics and articles. The filament yarns and fibers described herein may be coated with at least one finish and, in some cases, may be coated with two or more finishes selected to enhance the properties of the fibers. Staple fibers as described herein may be used to produce nonwoven webs that are strong, soft, absorbent, and biodegradable, and may be used in wet or dry nonwoven articles for a variety personal care, medical, industrial, and commercial applications. 1. A nonwoven web comprising a plurality of cellulose acetate staple fibers , wherein said cellulose acetate staple fibers have a crimp frequency of less than about 24 crimps per inch (CPI) , and wherein said cellulose acetate staple fibers are at least partially coated with at least one finish ,wherein said nonwoven web has one or more of the following characteristics (i) through (v):{'sup': '2', '(i) a wet tensile strength in the machine direction (MD) in the range of about 10 to about 1000 Nm/kg, measured according to NWSP 110.4 Option A with a 1-inch sample strip and normalized for the basis weight of the nonwoven;'}{'sup': '2', '(ii) a wet tensile strength in the cross direction (CD) in the range of 10 about to about 1000 Nm/kg, measured according to NWSP 110.4 Option A with a 1-inch sample strip and normalized for the basis weight of the nonwoven;'}{'sup': '2', '(iii) a dry tensile strength in the machine direction (MD) in the range of about 10 to about 2000 Nm/kg, measured according to NWSP 110.4 Option A with a 1-inch sample strip and normalized for the basis weight of the nonwoven;'}{'sup': '2', '(iv) a dry tensile strength in the cross direction (CD) in the range of about 10 to about 2000 Nm/kg, measured according to NWSP 110.4 Option A with a 1-inch sample strip and normalized for the basis weight of the nonwoven;'}(v) ...

Подробнее
Номер записи: 22
04-01-2018 дата публикации

System, method and recording medium for emergency vehicle route guidance

Номер: US20180005523A1
Автор: Amos Cahan, Ruchi Mahindru, Syed Yousaf Shah, Valentina Salapura
Принадлежит: International Business Machines Corp

An emergency vehicle route management method, system, and non-transitory computer readable medium, include analyzing a map to plot roads, a user including user data, and an emergency vehicle including emergency vehicle data on the map, determining an intersection of the roads within a predetermined radius of the emergency vehicle, and delivering an action for the user based on a road on a path of the emergency vehicle being determined by the determining to intersect with a road of the user.

Подробнее
Номер записи: 23
12-01-2017 дата публикации

PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF

Номер: US20170007597A1
Автор: Bazhina Nataliya, Donato, Fabian Steven R., III George Joseph, Lokhnauth John, Megati Sreenivasulu, Melucci Charles, Ofslager Christian, Patel Niketa, Radebaugh Galen, SHAH Syed M., Szeliga Jan, Zhang Huyi, Zhu Tianmin
Принадлежит:

The present invention provides a compound of formula I: 2. The composition of claim 1 , wherein the Brønsted acid is selected from the group consisting of a hydrogen halide claim 1 , a carboxylic acid claim 1 , a sulfonic acid claim 1 , a sulfuric acid claim 1 , and a phosphoric acid.3. The composition of claim 1 , wherein A is selected from the group consisting of chloride claim 1 , bromide claim 1 , iodide claim 1 , fluoride claim 1 , sulfate claim 1 , bisulfate claim 1 , tartrate claim 1 , nitrate claim 1 , citrate claim 1 , bitartrate claim 1 , carbonate claim 1 , phosphate claim 1 , malate claim 1 , maleate claim 1 , fumarate claim 1 , sulfonate claim 1 , methylsulfonate claim 1 , formate claim 1 , carboxylate claim 1 , methylsulfate claim 1 , trifluoroacetate claim 1 , and succinate.4. The composition of claim 3 , wherein A is bromide.5. The composition of claim 1 , wherein X is selected from the group consisting of chloride claim 1 , bromide claim 1 , iodide claim 1 , fluoride claim 1 , sulfate claim 1 , bisulfate claim 1 , tartrate claim 1 , nitrate claim 1 , citrate claim 1 , bitartrate claim 1 , carbonate claim 1 , phosphate claim 1 , malate claim 1 , maleate claim 1 , fumarate claim 1 , sulfonate claim 1 , methylsulfonate claim 1 , formate claim 1 , carboxylate claim 1 , methylsulfate claim 1 , trifluoroacetate claim 1 , and succinate.6. The composition of claim 5 , wherein X is bromide.7. The composition of claim 1 , wherein the composition contains tungsten in an amount of less than about 60 parts per billion.9. The composition of claim 1 , wherein the compound of formula III is contained within a package that is substantially free of tungsten.10. The composition of claim 9 , wherein the package is selected from the group consisting of: a syringe claim 9 , a vial and an ampoule.11. The composition of claim 10 , wherein the package is a syringe.12. The composition of claim 1 , wherein the composition is a solid composition.13. The composition of claim 12 ...

Подробнее
Номер записи: 24
27-01-2022 дата публикации

FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF

Номер: US20220023200A1
Автор: Bazhina Nataliya, Fawzi Mahdi B., Ofslager Christian, SHAH Syed M.
Принадлежит: Wyeth, LLC

The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids. 1. A pharmaceutical composition comprising an effective amount of methylnaltrexone or a pharmaceutically acceptable salt thereof , calcium ethylenediaminetriacetic acid (EDTA) or a calcium salt EDTA derivative , and glycine in an aqueous solution , wherein the solution has a pH of about 3 to 4 , and wherein the composition further comprises at least one opioid.2. The pharmaceutical composition of claim 1 , wherein the salt of methylnaltrexone comprises methylnaltrexone bromide.3. The pharmaceutical composition of claim 1 , wherein the composition comprises about 5 mg to about 40 mg of methylnaltrexone or a pharmaceutically acceptable salt thereof.4. The pharmaceutical composition of claim 3 , wherein the composition comprises about 8 mg to about 12 mg of methylnaltrexone or a pharmaceutically acceptable salt thereof.5. The pharmaceutical composition of claim 2 , wherein the composition comprises about 10 mg/mL to about 20 mg/mL methylnaltrexone bromide.6. The pharmaceutical composition of claim 1 , wherein the composition comprises about 0.2 mg/mL to about 0.8 mg/mL of the calciumethylenediaminetriacetic acid (EDTA) or the calcium salt EDTA derivative.7. The pharmaceutical composition of claim 1 , wherein the composition comprises about 0.1 mg/mL to about 0.8 mg/mL of the glycine.8. The pharmaceutical composition of claim 1 , wherein the calcium salt EDTA derivative comprises calcium EDTA disodium.9. The pharmaceutical composition of claim 1 , wherein the glycine comprises glycine HCl.10. The pharmaceutical composition of claim 1 , wherein the solution has a pH of about 3.4 to about 3.6.11. The pharmaceutical composition of claim 1 , wherein the solution has a pH of about 3.5.12. The ...

Подробнее
Номер записи: 25
09-01-2020 дата публикации

CELLULOSE ACETATE FIBERS IN NONWOVEN FABRICS

Номер: US20200010980A1
Автор: Appling Yancey, Gaynor Scott Gregory, Ghosh Koushik, Hassan Mohammad Abouelreesh, Izallalen Mounir, Posa James M., Qin Guo Wei, Shah Syed Ali, Spruell Jason Michael, Steach Jeremy Kenneth
Принадлежит: EASTMAN CHEMICAL COMPANY

Staple fibers and filament yarns formed from cellulose esters, such as cellulose acetate, are described herein, along with methods of making the fibers and their use in nonwoven fabrics and articles. The filament yarns and fibers described herein may be coated with at least one finish and, in some cases, may be coated with two or more finishes selected to enhance the properties of the fibers. Staple fibers as described herein may be used to produce nonwoven webs that are strong, soft, absorbent, and biodegradable, and may be used in wet or dry nonwoven articles for a variety personal care, medical, industrial, and commercial applications. 1. A staple fiber formed from cellulose acetate and at least partially coated with at least one ionic fiber finish , wherein said fiber has a surface resistivity , expressed as log R , of not more than about 11.2. The fiber of claim 1 , wherein said fiber has a static half-life of not more than about 25 seconds and wherein a plurality of said fibers exhibit a fiber-to-fiber staple pad coefficient of friction of at least about 0.1.3. The fiber of claim 1 , wherein a plurality of said fibers exhibit a fiber-to-fiber staple pad coefficient of friction of at least about 0.10 and a plurality of said fibers exhibit a fiber-to-metal staple pad coefficient of friction of at least about 0.20.4. The fiber of claim 1 , wherein said fiber is not coated with a spinning finish and is coated with at least one top-coat finish in an amount of not more than about 0.4% FOY claim 1 , wherein said top-coat finish comprises said ionic fiber finish claim 1 , and wherein said staple fiber has a crimp frequency in the range of from about 10 to about 17 crimps per inch (CPI).5. The fiber of claim 1 , wherein said fiber has a denier per filament in the range of from about 0.5 to about 3 claim 1 , a crimp frequency in the range of from about 8 to about 24 CPI claim 1 , a length in the range of from about 3 to about 75 mm claim 1 , and a Y-shaped or round ...

Подробнее
Номер записи: 26
15-01-2015 дата публикации

COATED ICE MELTING COMPOSITIONS

Номер: US20150014576A1
Автор: Matuszczak Stephen, Shah Syed Ali, Waatti Kurt John
Принадлежит:

Ice melting compositions, methods for manufacturing ice melting compositions, and methods for melting ice are disclosed. The ice melting compositions can include a coarse deicing particle nucleus and a fine deicing particle coating substantially surrounding the coarse deicing particle nucleus. The fine particle coating can be attached or bonded to the coarse particle nucleus with a binder. The coarse particle nucleus and the fine particle coating can have a variety of particle sizes. 1. An ice melting composition comprising:a coarse deicing particle nucleus,a fine deicing particle coating substantially surrounding the coarse deicing particle nucleus and bonded to the coarse deicing particle nucleus with a binder, wherein the binder is a sodium chloride brine with yellow prussiate of soda.2. The ice melting composition of claim 1 , wherein the ice melting composition comprises from about 60% to about 97% of the coarse deicing particle nucleus claim 1 , from about 0.5% to about 6% of the binder claim 1 , and from about 3% to about 35% of the fine deicing particle coating.3. The ice melting composition of claim 1 , wherein the coarse deicing particle nucleus comprises sodium chloride.4. The ice melting composition of claim 1 , wherein the fine deicing particle coating comprises fine particles of sodium chloride.5. The ice melting composition of claim 1 , wherein the fine deicing particle coating consists of fine particles of sodium chloride.6. The ice melting composition of claim 1 , wherein the sodium chloride brine is saturated.7. The ice melting composition of claim 1 , wherein the coarse deicing particle nucleus has a particle size range from about 500 μm to about 10 claim 1 ,000 μm and the fine deicing particle coating comprises fine deicing particles having a particle size range from about 20 μm to about 600 μm.8. The ice melting composition of claim 1 , wherein the fine deicing particle coating comprises fine deicing particles having a particle size range from ...

Подробнее
Номер записи: 27
03-02-2022 дата публикации

Relay based system to launch a projectile

Номер: US20220034624A1
Автор: Bilal Syed Ali Shah, Faraz Rahman, Ishaq Nadeem Khan, Mikaeel Faisal Khan, Mirza Faizan, Mirza Rizwan, Mohammed Omer Shakoor, Shoaib Ali, Zainab Khan
Принадлежит: Individual

A series of the relay of the electromagnetic launcher with a gun and a floating launch platform to launch projectiles in space, wherein the projectile is accelerated along a path using electromagnetic force until the projectile reaches a desired direction and position. The direction of the path is determined by orienting the path in the desired direction using a catcher. the catcher and rail gun projectile as high above as possible, coming close to near space. When the said projectile will reach the last platform, it will be launched by the railgun and ignite its rocket engine to take the payload in space or as required to eliminate the need for large rocket boosters to launch the projectile.

Подробнее
Номер записи: 28
03-02-2022 дата публикации

AUTOMATED MACHINE LEARNING PIPELINE GENERATION

Номер: US20220036246A1
Автор: BRAMBLE Gregory, Chen Bei, Dang Xuan-Hong, Gan Chuang, Han Si Er, Kirchner Peter Daniel, PATEL Dhavalkumar C., Samulowitz Horst Cornelius, Sathe Saket, SHAH SYED YOUSAF, Vu Long, WANG Dakuo, Wang Jun, Xu Jing James, YANG Ji Hui
Принадлежит:

Techniques regarding one or more automated machine learning processes that analyze time series data are provided. For example, one or more embodiments described herein can comprise a system, which can comprise a memory that can store computer executable components. The system can also comprise a processor, operably coupled to the memory, and that can execute the computer executable components stored in the memory. The computer executable components can comprise a time series analysis component that selects a machine learning pipeline for meta transfer learning on time series data by sequentially allocating subsets of training data from the time series data amongst a plurality of machine learning pipeline candidates. 1. A system , comprising:a memory that stores computer executable components; and 'a time series analysis component that selects a machine learning pipeline for meta transfer learning on time series data by sequentially allocating subsets of training data from the time series data amongst a plurality of machine learning pipeline candidates.', 'a processor, operably coupled to the memory, and that executes the computer executable components stored in the memory, wherein the computer executable components comprise2. The system of claim 1 , wherein the time series analysis component further selects the machine learning pipeline based on a runtime threshold that restricts an amount of time allotted to execution of a machine learning task.3. The system of claim 1 , further comprising:a use case component that depopulates the plurality of machine learning pipeline candidates based on a domain of the time series data.4. The system of claim 1 , further comprising:a learning component that ranks the machine learning pipeline amongst the plurality of machine learning pipeline candidates based on meta-data derived from historic execution of the machine learning pipeline and a characteristic of the time series data.5. The system of claim 4 , further comprising:a ...

Подробнее
Номер записи: 29
03-02-2022 дата публикации

VISUALIZATION OF A MODEL SELECTION PROCESS IN AN AUTOMATED MODEL SELECTION SYSTEM

Номер: US20220036610A1
Автор: Chaudhary Arunima, Chen Bei, EVERSMAN John Dillon, Gan Chuang, Han Si Er, PATEL Dhavalkumar C., SHAH SYED YOUSAF, SUPADULYA Voranouth, Valente Abel, Vu Long, WANG Dakuo, Wang Jun, Weidele Daniel Karl I., Xu Jing James, YANG Ji Hui
Принадлежит:

Systems, computer-implemented methods, and computer program products to facilitate visualization of a model selection process are provided. According to an embodiment, a system can comprise a memory that stores computer executable components and a processor that executes the computer executable components stored in the memory. The computer executable components can comprise an interaction backend handler component that obtains one or more assessment metrics of a model pipeline candidate. The computer executable components can further comprise a visualization render component that renders a progress visualization of the model pipeline candidate based on the one or more assessment metrics. 1. A system , comprising:a memory that stores computer executable components; and an interaction backend handler component that obtains one or more assessment metrics of a model pipeline candidate and second model pipeline candidate; and', 'a visualization render component that concurrently renders a progress visualization of the model pipeline candidate and a second progress visualization of the second model pipeline candidate based on the one or more assessment metrics, and wherein the progress visualization and the second visualization comprises a tree based visualization., 'a processor that executes the computer executable components stored in the memory, wherein the computer executable components comprise2. The system of claim 1 , wherein the one or more assessment metrics are selected from a group consisting of an optimization metric claim 1 , a performance metric claim 1 , a data allocation metric claim 1 , a training data used metric claim 1 , and a build time metric.3. The system of claim 1 , wherein the visualization render component further renders the progress visualization in at least one of a progress map claim 1 , a relationship map claim 1 , or a leaderboard.4. The system of claim 1 , wherein the progress visualization comprises a visual representation of the one or ...

Подробнее
Номер записи: 30
28-01-2016 дата публикации

BIOADHESIVE AND BIODEGRADABLE AND FORMULATIONS THAT PROVIDE SUSTAINED RELEASE OF ANTIMICROBIALS, BACTERIOPHAGES AND ANTI-INFLAMMATORY MEDICATIONS FOR INACTIVATION OF BIOFILMS AND THE TREATMENT OF RHINOSINUSITIS AND OTHER INFECTIONS

Номер: US20160022595A1
Автор: Domb Abraham, HASSAN FRED, SHAH Syed M., Shikani Alan H.
Принадлежит:

Described is a composition comprising one or more active ingredients coated, dispersed, or dissolved with a mucoadhesive polymer. Although subject to multiple uses, the composition, in some embodiments, is usable for treating rhinosinusitis. 1. A pharmaceutically acceptable composition , comprising one or more mucoadhesive polymers coating , dispersing , or dissolving one or more active ingredients.2. The pharmaceutically acceptable composition of claim 1 , wherein the one or more active ingredients are in the form of solid particles having an average size ranging from 0.050 to 15 microns (μm).3. The pharmaceutically acceptable composition of claim 1 , wherein the amount of one or more active ingredients ranges from 1 to 50 percent by weight (w/w %) of the one or more active ingredients and one or more mucoadhesive polymers.4. The pharmaceutically acceptable composition of claim 1 , wherein the one or more active ingredients are chosen from anti-inflammatory agents claim 1 , antimicrobial active agents claim 1 , antihistamines claim 1 , and nasal decongestants.5. The pharmaceutically acceptable composition of claim 1 , wherein the one or more active ingredients are chosen from anti-inflammatory agents and antimicrobial/antifungal/antiinfective active agents.6. The pharmaceutically acceptable composition of claim 1 , wherein the one or more active ingredients is a bacteriophage.7. The pharmaceutically acceptable composition of claim 1 , wherein the one or more active ingredients is a combination of a bacteriophage and/ or an anti-inflammatory agent and/or antimicrobial claim 1 , antifungal claim 1 , and antiinfective active agent .8. The pharmaceutically acceptable composition of claim 7 , wherein the solid pharmaceutically acceptable carrier is coated with one or more second mucoadhesive polymers9. The pharmaceutically acceptable composition of claim 1 , wherein dispersion of the active ingredients occurs following a concentration gradient claim 1 , with the highest ...

Подробнее
Номер записи: 31
28-01-2016 дата публикации

L-Menthol Dosage Forms Having A Proteinaceous Coating For Enhanced Storage Stability

Номер: US20160022597A1
Автор: HASSAN FRED, SHAH Syed M.
Принадлежит:

A storage stable L-menthol composition including a tablet, caplet, capsule, or sachet dosage form has therein a core containing crystalline L-menthol and at least one pharmaceutical excipient. A proteinaceous coating of a continuous film of proteinaceous material is over the core. The film is effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days. The dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder. 1. A storage stable L-menthol composition comprising a tablet , caplet , capsule , or sachet dosage form having:a core containing crystalline L-menthol and at least one pharmaceutical excipient; anda proteinaceous coating of a continuous film of proteinaceous material over the core forming a proteinaceous coated core, the film being effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days;wherein the dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder.2. The storage stable L-menthol composition of claim 1 , wherein the crystalline L-menthol is in the form of a polycrystalline powder.3. The storage stable L-menthol composition of claim 1 , wherein the proteinaceous material includes gelatin.4. The storage stable L-menthol composition of claim 1 , wherein the proteinaceous material includes acid bone gelatin.5. The storage stable L-menthol composition of claim 1 , wherein the tablet claim 1 , caplet claim 1 , capsule claim 1 , or sachet dosage form also has an enteric coating over the proteinaceous coated core.6. The storage stable L-menthol composition of claim 5 , wherein the enteric coating comprises a methacrylic acid based material.7. The storage stable L- ...

Подробнее
Номер записи: 32
22-01-2015 дата публикации

FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF

Номер: US20150025100A1
Автор: Bazhina Nataliya, Fawzi Mahdi B., Ofslager Christian, SHAH Syed M.
Принадлежит: Progenics Pharmaceuticals, Inc.

The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids. 1. A pharmaceutical composition comprising an effective amount of methylnaltrexone or a pharmaceutically acceptable salt thereof , calcium ethylenediaminetriacetic acid (EDTA) or a calcium salt EDTA derivative , and glycine in an aqueous solution , wherein the solution has a pH of about 3 to 4.2. The pharmaceutical composition of claim 1 , wherein the salt of methylnaltrexone comprises methylnaltrexone bromide.3. The pharmaceutical composition of claim 1 , wherein the composition comprises about 5 mg to about 40 mg of methylnaltrexone or a pharmaceutically acceptable salt thereof.4. The pharmaceutical composition of claim 1 , wherein the composition comprises about 8 mg to about 12 mg of methylnaltrexone or a pharmaceutically acceptable salt thereof.5. The pharmaceutical composition of claim 1 , wherein the calcium salt EDTA derivative comprises calcium EDTA disodium.6. The pharmaceutical composition of claim 1 , wherein the composition comprises about 0.2 to about 0.8 mg/mL of calcium ethylenediaminetriacetic acid (EDTA) or a calcium salt EDTA derivative.7. The pharmaceutical composition of claim 1 , wherein the composition comprises about 0.4 mg/mL of calcium ethylenediaminetriacetic acid (EDTA) or a calcium salt EDTA derivative.8. The pharmaceutical composition of claim 1 , wherein the glycine comprises glycine HCl.9. The pharmaceutical composition of claim 1 , wherein the composition comprises about 0.3 mg/ml glycine.10. The pharmaceutical composition of claim 1 , wherein the solution has a pH of about 3.4 to about 3.6.11. The pharmaceutical composition of claim 1 , wherein the solution has a pH of about 3.5.12. The pharmaceutical composition of claim 1 , further comprising sodium chloride. ...

Подробнее
Номер записи: 33
31-01-2019 дата публикации

Packaging For Solid Dosage Forms Of Melatonin With A High Citric Acid Concentration

Номер: US20190031417A1
Автор: HASSAN DANIEL, HASSAN FRED, SHAH Syed M.
Принадлежит:

Melatonin tablets with a high concentration of citric acid are packaged in a blister package that enhances storage stability. Such a packaging material includes a blister film forming a cavity holding the tablet therein. The blister film includes a polyvinyl chloride (PVC) film having a thickness of 180 μm to 270 μm coated with a polyvinylidene chloride (PVDC) coating having a coating weight of 110 g/mto 130 g/m. An aluminum foil lid closes the cavity and encapsulates the tablet within the blister film and lid. The lid has a thickness of 20 μm to 30 μm. 1. A product comprising:an oral tablet dosage form including melatonin and citric acid in a polymer matrix;{'sup': 2', '2, 'a blister film forming a cavity holding the tablet therein, the blister film including a polyvinyl chloride (PVC) film having a thickness of 180 μm to 270 μm coated with a polyvinylidene chloride (PVDC) coating having a coating weight of 110 g/mto 130 g/m; and'}an aluminum foil lid closing the cavity and encapsulating the tablet within the blister film and lid, the lid having a thickness of 20 μm to 30 μm.2. The product of claim 1 , wherein the PVC film has a thickness of 190 μm to 260 μm.3. The product of claim 1 , wherein the PVDC coating has a coating weight of about 120 g/m.4. The product of claim 1 , wherein the lid has a thickness of about 25 μm.5. The product of claim 1 , wherein the PVC film has a thickness of 190 μm to 260 μm claim 1 , the PVDC coating has a coating weight of about 120 g/m claim 1 , and the lid has a thickness of about 25 μm.6. The product of claim 1 , wherein the tablet includes an opalescent outer coating containing mica particles as a light barrier.7. A product comprising:an oral tablet dosage form including melatonin and citric acid in a polymer matrix; [{'sup': 2', '2, 'a blister film forming a cavity holding the tablet therein, the blister film including a polyvinyl chloride (PVC) film having a thickness of 180 μm to 270 μm coated with a polyvinylidene chloride ( ...

Подробнее
Номер записи: 34
11-02-2016 дата публикации

Enteric Coated Multiparticulate Composition With Proteinaceous Coating For Improved Storage Stability

Номер: US20160038429A1
Автор: HASSAN FRED, SHAH Syed M.
Принадлежит:

A storage stable L-menthol composition includes a tablet, caplet, capsule, or sachet dosage form. The dosage form has (a) a plurality of individual cores containing an L-menthol source and at least one pharmaceutical excipient and (b) a proteinaceous coating of a continuous film of proteinaceous material over the individual cores forming a plurality of proteinaceous coated individual cores. The film is effective to substantially prevent L-menthol in the L-menthol source from leaving the individual cores when stored at a temperature of 40 degrees C. and 75% relative humidity for at least 1 day. The dosage form contains an effective amount of the L-menthol source for treating a gastrointestinal disorder. 1. A storage stable L-menthol composition comprising: (a) a plurality of individual cores containing an L-menthol source and at least one pharmaceutical excipient; and', '(b) a proteinaceous coating of a continuous film of proteinaceous material over the individual cores forming a plurality of proteinaceous coated individual cores, the film being effective to substantially prevent L-menthol in the L-menthol source from leaving the individual cores when stored at a temperature of 40 degrees C. and 75% relative humidity for at least 1 day;, 'a tablet, caplet, capsule, or sachet dosage form comprisingwherein the dosage form contains an effective amount of the L-menthol source for treating a gastrointestinal disorder.2. The storage stable L-menthol composition of claim 1 , wherein the film is effective to substantially prevent L-menthol in the L-menthol source from leaving the core when the proteinaceous material coated core is stored at 40 degrees C. and 75% relative for at least up to 30 days.3. The storage stable L-menthol composition of claim 1 , wherein the L-menthol in the L-menthol source is in crystalline form.4. The storage stable L-menthol composition of claim 1 , wherein the L-menthol in the L-menthol source is in polycrystalline powder form.5. The storage ...

Подробнее
Номер записи: 35
12-02-2015 дата публикации

Enteric Coated Multiparticulate Composition With Proteinaceous Subcoat

Номер: US20150044294A1
Автор: HASSAN FRED, SHAH Syed M.
Принадлежит:

A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders. 1. A multiparticulate dosage form comprising a plurality of individual enteric coated particulates having (a) a solid core containing an effective amount of at least one volatile terpene-based active ingredient , (b) a continuous proteinaceous subcoating over the core , and (c) an enteric coating over the subcoating , the subcoating being effective to prevent the volatile terpene-based active ingredient(s) from substantially penetrating the subcoating and contacting the enteric coating when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days.2. The multiparticulate composition of claim 1 , wherein the at least one volatile terpene-based active ingredient includes L-menthol from an at least 80% pure L-menthol source.3. The multiparticulate composition of claim 1 , wherein the at least one volatile terpene-based active ingredient includes peppermint oil.4. The multiparticulate composition of claim 1 , wherein the at least one volatile terpene-based active ingredient includes L-menthol from an at least 80% pure L-menthol source dissolved in peppermint oil.5. The multiparticulate composition of claim 1 , wherein the at least one volatile terpene-based active ingredient includes both L-menthol and caraway oil.6. The multiparticulate composition of claim 1 , wherein the at least one volatile terpene-based active ingredient includes ...

Подробнее
Номер записи: 36
24-02-2022 дата публикации

TYRE SIDEWALL IMAGING METHOD

Номер: US20220058417A1
Автор: Codd Alexander Paul, Kazmi Syed Wajahat Ali Shah, Nabney Ian Thomas, VOGIATZIS George
Принадлежит:

A computer implemented method for generating a region of interest on a digital image of a sidewall of a tyre, the sidewall having one or more embossed and/or engraved markings, is provided. The method comprises generating a histogram of oriented gradients feature map of the digital image, inputting the histogram of oriented gradients feature map into a trained convolutional neural network, wherein said trained convolutional neural network is configured to output a first probability based on the input histogram of oriented gradients feature map that a region of pixels of the digital image contains the embossed and/or engraved markings, and if the first probability is at or above a first predetermined threshold, accepting said region of pixels as said region of interest. 1. A computer implemented method for generating a region of interest on a digital image of a sidewall of a tyre , the sidewall having one or more embossed and/or engraved markings , the method comprising:generating a histogram of oriented gradients feature map of the digital image;inputting the histogram of oriented gradients feature map into a trained neural network, wherein the trained neural network is configured to output a first probability based on the input histogram of oriented gradients feature map that a region of pixels of the digital image contains the embossed and/or engraved markings; andif the first probability is at or above a first predetermined threshold, accepting the region of pixels as the region of interest.2. The computer implemented method of claim 1 , wherein generating a histogram of oriented gradients feature map is performed by a stack of convolutional filters in a trained convolutional neural network.3. The computer implemented method of claim 1 , wherein generating a histogram of oriented gradients feature map is performed by a histogram of oriented gradients generator separated from the trained neural network.4. The computer implemented method of claim 1 , wherein the ...

Подробнее
Номер записи: 37
19-02-2015 дата публикации

Enteric Coated Multiparticulate Composition With Proteinaceous Subcoat

Номер: US20150050352A1
Автор: HASSAN FRED, SHAH Syed M.
Принадлежит:

A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders. 1. A method of treating a gastrointestinal disorder in a human subject , the method comprising administering to the subject a multiparticulate dosage form composition effective to treat a gastrointestinal disorder in the subject , the composition comprising a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings.2. The method of claim 1 , wherein administering is performed enterally.3. The method of claim 2 , wherein administering is performed orally.4. The method of claim 1 , wherein the one or more terpene-based active ingredients include L-menthol from an at least 80% pure L-menthol source dissolved in a terpene-containing essential oil.5. The method of claim 1 , wherein the one or more terpene-based active ingredients include both L-menthol and caraway oil.6. The method of claim 1 , wherein the one or more terpene-based active ingredients include L-menthol from an at least 80% pure L-menthol source dissolved in peppermint oil.7. The method of claim 1 , wherein the one or more terpene-based active ingredients include both peppermint oil and caraway oil.8. The method of claim 1 , wherein the one or more terpene-based active ingredients include both L-menthol and ...

Подробнее
Номер записи: 38
13-02-2020 дата публикации

METHODS AND SYSTEM FOR CHARACTERISING TREMORS

Номер: US20200046259A1
Автор: BRITTAIN John-Stuart, DI BIASE Lazzaro, LAZZARO Vincenzo Di, PETER Brown, SHAH Syed Ahmar
Принадлежит:

A method of characterising tremor stability in a subject is described for a subject having an involuntary tremor symptomatic of a neurological disorder. The method comprising: identifying a series of tremor cycles from measured tremor data of the subject, said tremor cycles measuring periodic variation in movement of the subject due to the tremor; determining an instantaneous frequency for each tremor cycle and collating the instantaneous frequencies; determining an instantaneous variation between the instantaneous frequencies of each pair of adjacent tremor cycles within the series; comparing the instantaneous variation to the collation of determined instantaneous frequencies to determine a distribution of instantaneous variations; and determining an index value of the distribution of the instantaneous variations, said index value defining the stability of the tremor. 1. A method of characterising tremor stability in a subject , said subject having an involuntary tremor symptomatic of a neurological disorder , the method comprising:identifying a series of tremor cycles from measured tremor data of the subject, said tremor cycles measuring periodic variation in movement of the subject due to the tremor;determining an instantaneous frequency for each tremor cycle and collating the instantaneous frequencies;determining an instantaneous variation between the instantaneous frequencies of each pair of adjacent tremor cycles within the series;comparing the instantaneous variation to the collation of determined instantaneous frequencies to determine a distribution of instantaneous variations; anddetermining an index value of the distribution of the instantaneous variations, said index value defining the stability of the tremor.2. A method as claimed in claim 1 , wherein the measured tremor data is obtained using a triaxial accelerometer.3. A method as claimed in claim 1 , wherein the measured tremor data is obtained using a velocity-transducing laser.4. A method as claimed ...

Подробнее
Номер записи: 39
10-03-2022 дата публикации

Enteric Coated Multiparticulate Compositions With A Proteinaceous Subcoat

Номер: US20220071912A1
Автор: HASSAN FRED, SHAH Syed M.
Принадлежит:

A method of treating a gastrointestinal disorder includes administering to a patient an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm. The individual spheroidal enteric coated cores have (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating. The multiparticulate dosage form is configured to release most of the menthol in the area of the GI tract where the inflammation is occurring. 1. A method of treating irritable bowel syndrome , the method comprising:administering to a patient having irritable bowel syndrome an effective amount of a multiparticulate dosage form including a plurality of individual spheroidal enteric coated cores having a diameter of 0.1 mm to 3 mm;the individual spheroidal enteric coated cores comprising (a) a core including menthol, (b) a proteinaceous subcoating over the core, and (c) an enteric coating over the proteinaceous subcoating; andwherein the multiparticulate dosage form is configured to release most of the menthol in a small intestine of the patient.2. The method of claim 1 , wherein the multiparticulate dosage form is configured to gradually release the menthol into the small intestine over 4 to 8 hours from passing a pyloric sphincter of the patient.3. The method of claim 1 , wherein the multiparticulate dosage form is configured to release 20% or less of the menthol into a stomach of the patient and 20% or less of the menthol into a colon of the patient.4. The method of claim 1 , wherein the effective amount is effective for relieving symptoms of irritable bowel syndrome including at least one of abdominal pain claim 1 , cramps claim 1 , and diarrhea.5. The method of claim 1 , wherein the individual spheroidal enteric coated cores comprise 10% w/w to 35% w/w menthol claim 1 , 40% w/w to 75% w/w microcrystalline cellulose claim 1 , and 2% w/w ...

Подробнее
Номер записи: 40
10-03-2022 дата публикации

APPARATUSES AND METHODS FOR SETTING AN ELECTRICAL DOSE

Номер: US20220072310A1
Автор: Fang Zi-Ping, SYED SHAH Nemath
Принадлежит:

Methods and apparatuses for setting a therapeutic dose of a neuromodulator implanted into a patient are described. The therapeutic dose typically includes a therapeutic dose duration including a ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which the voltage is sustained at the peak modulation voltage. The methods and apparatuses described herein may use a testing ramp to identify a peak modulation voltage that is patient-specific and provides a maximized therapeutic effect while remaining comfortably tolerable by the patient during the application of energy by the neuromodulator. 1. A method of setting therapeutic doses of a neuromodulator implanted into a patient , wherein each of the therapeutic doses comprises a therapeutic dose duration including a therapy ramp-up time to reach a peak modulation voltage and a sustained peak modulation time during which voltage is sustained at the peak modulation voltage , the method comprising:applying a test voltage ramp from the neuromodulator implanted into the patient;determining a target sensation intensity modulation voltage that is specific to the patient from the test voltage ramp;calculating an estimated peak modulation voltage as a function of the target sensation intensity modulation voltage and the therapy ramp-up time to reach the peak modulation voltage;setting a first therapeutic dose using the estimated peak modulation voltage; andsetting a second therapeutic dose using a percentage of the estimated peak modulation voltage.2. The method of claim 1 , wherein the therapeutic dose duration of the first therapeutic dose is the same as the therapeutic dose duration of the second therapeutic dose.3. The method of claim 1 , wherein a duration of applying the estimated peak modulation voltage of the first therapeutic dose is greater than a duration of applying the estimated peak modulation voltage of the second therapeutic dose.4. The method of claim 1 , wherein the ...

Подробнее
Номер записи: 41
05-03-2015 дата публикации

Multiparticulate L-Menthol Formulations and Related Methods

Номер: US20150064261A1
Автор: HASSAN DANIEL, HASSAN FRED, HASSAN SARAH, SHAH Syed M.
Принадлежит:

A multiparticulate dosage form includes a plurality of individual spheroidal enteric coated particulates having (a) a diameter of 0.1 to 2.5 mm; (b) a solid core containing an effective amount of a combination of an L-menthol source and a terpene-based essential oil; (c) a continuous proteinaceous subcoating over the core; and (d) an enteric coating over the subcoating. The multiparticulate dosage form can be used to treat gastrointestinal disorders. 1. A multiparticulate dosage form comprising a plurality of individual spheroidal enteric coated particulates having (a) a diameter of 0.1 to 2.5 mm; (b) a solid core containing an effective amount of a combination of an L-menthol source and a terpene-based essential oil; (c) a continuous proteinaceous subcoating over the core; and (d) an enteric coating over the subcoating.2. The multiparticulate dosage form of claim 1 , wherein the effective amount is an amount effective for treating a gastrointestinal disorder.3. The multiparticulate dosage form of claim 1 , wherein the L-menthol source is at least 80% pure L-menthol.4. The multiparticulate dosage form of claim 3 , wherein the L-menthol source is crystalline L-menthol.5. The multiparticulate dosage form of claim 4 , wherein the crystalline L-menthol is dissolved in the terpene-based essential oil.6. The multiparticulate dosage form of claim 5 , wherein the terpene-based essential oil is peppermint oil.7. The multiparticulate dosage form of claim 5 , wherein the terpene-based essential oil is caraway oil.8. The multiparticulate dosage form of claim 3 , wherein the terpene-based essential oil is peppermint oil.9. The multiparticulate dosage form of claim 3 , wherein the terpene-based essential oil is caraway oil.10. The multiparticulate dosage form of claim 1 , wherein the proteinaceous subcoating is a dried proteinaceous gel.11. The multiparticulate dosage form of claim 1 , wherein the proteinaceous subcoating is a gelatin film.12. The multiparticulate dosage form of ...

Подробнее
Номер записи: 42
17-03-2022 дата публикации

SOLID MICRONIZED MELATONIN COMPOSITION

Номер: US20220079921A1
Автор: HASSAN DANIEL, SHAH Syed M.
Принадлежит:

A melatonin composition has a dry granulation including a melatonin powder with a median melatonin particle size of 5 μm to 40 μm, a carboxylic acid powder, and a powder of a hydrogel-forming polymer. The dry granulation is combined with pharmaceutical excipients in a dry orally ingestible pharmaceutical dosage form adapted to absorb water upon ingestion and form a hydrogel including soluble melatonin and soluble carboxylic acid in the hydrogel, the carboxylic acid being in an amount sufficient to impart a pH of 4.4 or less to the hydrogel after ingestion. 1. A method of making a melatonin dosage form , the method comprising:forming granules by dry granulating a melatonin powder having a median melatonin particle size of 5 μm to 40 μm, a carboxylic acid powder, and a powder of a hydrogel-forming polymer to form a dry granulation having a substantially uniform distribution of melatonin powder, carboxylic acid powder, and powder of the hydrogel-forming polymer; andplacing the granules into a dry orally ingestible pharmaceutical dosage form, the dosage form being adapted to absorb water upon ingestion and form a hydrogel including soluble melatonin and soluble carboxylic acid in the hydrogel, the carboxylic acid being in an amount sufficient to impart a pH of 4.4 or less to the hydrogel after ingestion.2. The method of claim 1 , wherein dry granulating is performed without including a liquid solvent.3. The method of claim 1 , wherein the dosage form is selected from the group consisting of a tablet claim 1 , capsule claim 1 , caplet claim 1 , and multiparticulate.4. The method of claim 1 , wherein the carboxylic acid is citric acid.5. The method of claim 1 , wherein a particle size of the carboxylic acid is greater than the particle size of the melatonin.6. The method of claim 1 , further comprising compacting the granules by roller compaction and/or slugging after the forming step and prior to the placing step.7. The method of claim 1 , wherein the dosage form ...

Подробнее
Номер записи: 43
10-03-2016 дата публикации

Controlled-Release Melatonin Compositions and Related Methods

Номер: US20160067186A1
Автор: HASSAN DANIEL, SHAH Syed M.
Принадлежит:

A method of treating a human subject in need of melatonin therapy includes administering to a human subject a compressed tablet comprising melatonin, citric acid, and a cellulosic polymer. The melatonin, citric acid, and cellulosic polymer combine after ingestion to form an acidic hydrogel that dissolves the melatonin and is effective to provide a first release dose of melatonin for assisting in inducement of sleep and a subsequent sustained release dose of melatonin for assisting in sustaining sleep while in the human subject's gastrointestinal tract. 1. A method of treating a human subject in need of melatonin therapy , the method comprising administering to a human subject a compressed tablet comprising an effective amount of melatonin , citric acid , and a cellulosic polymer that combine after ingestion to form an acidic hydrogel that dissolves the melatonin and is effective to provide a first release dose of melatonin for assisting in inducement of sleep and a subsequent sustained release dose of melatonin for assisting in sustaining sleep while in said human subject's gastrointestinal tract.2. The method of claim 1 , wherein said human subject is pre-identified as having a circadian rhythm disorder.3. The method of claim 1 , wherein said human subject is pre-identified as having melatonin deficiency.4. The method of claim 1 , wherein said tablet is effective to release approximately 50% of said melatonin in said tablet into the gastrointestinal tract within approximately two hours after oral ingestion.5. The method of claim 1 , wherein said tablet is effective to release substantially all of the remaining melatonin in said tablet into said human subject's gastrointestinal tract over approximately three to approximately ten hours after oral ingestion.6. The method of claim 5 , wherein said tablet is effective to release substantially all of the remaining melatonin in said tablet into said human subject's lower gastrointestinal tract over approximately three to ...

Подробнее
Номер записи: 44
10-03-2016 дата публикации

CRYSTAL FORMS OF (R)-N-METHYLNALTREXONE BROMIDE AND USES THEREOF

Номер: US20160068540A1
Автор: AL SHAREFFI Kadum A., Boyd Thomas A., Perez Julio, SHAH Syed M., Smolenskaya Valeriya N.
Принадлежит:

The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist. 2. The compound according to claim 1 , characterized in that the compound has one or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9 claim 1 , 8.18 claim 1 , 20.3 claim 1 , 21.44 claim 1 , 24.11 claim 1 , and 25.12 degrees 2-theta.3. The compound according to claim 2 , characterized in that the compound has two or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9 claim 2 , 8.18 claim 2 , 20.3 claim 2 , 21.44 claim 2 , 24.11 claim 2 , and 25.12 degrees 2-theta.4. The compound according to claim 3 , characterized in that the compound has three or more peaks in its X-ray powder diffraction pattern selected from those at about 7.9 claim 3 , 8.18 claim 3 , 20.3 claim 3 , 21.44 claim 3 , 24.11 claim 3 , and 25.12 degrees 2-theta.5. The compound according to claim 4 , characterized in that the compound has substantially all of the peaks in its X-ray powder diffraction pattern selected from those at about 7.9 claim 4 , 8.18 claim 4 , 10.64 claim 4 , 11.57 claim 4 , 12.68 claim 4 , 13.44 claim 4 , 13.89 claim 4 , 14.38 claim 4 , 15.42 claim 4 , 16.01 claim 4 , 16.39 claim 4 , 17.18 claim 4 , 19.89 claim 4 , 20.79 claim 4 , 21.44 claim 4 , 21.9 claim 4 , 23.35 claim 4 , 24.49 claim 4 , 24.87 claim 4 , 25.53 claim 4 , and 29.17 degrees 2-theta.7. The compound according to claim 6 , characterized in that the compound has an X-ray powder diffraction pattern substantially similar to that depicted in .827-. (canceled)30. The composition according to claim 29 , comprising Form A and amorphous Compound 1.31. A composition claim 29 , comprising at least two of Form B claim 29 , Form C claim 29 , Form D claim 29 , and amorphous Compound 1.32. A pharmaceutical composition comprising one or more of Form A claim 29 , Form B claim 29 , Form C claim 29 , Form D claim 29 , ...

Подробнее
Номер записи: 45
17-03-2022 дата публикации

NETWORK SECURITY ORCHESTRATION AND MANAGEMENT ACROSS DIFFERENT CLOUDS

Номер: US20220086189A1
Автор: Kulkarni Somashekhar Varun, Nguyen Toan Van, Romanescu Bogdan Florin, Shah Syed Abdullah, Singh Prabhat, Srinivasan Sriram, Vetrinadar Manohar Santhosh Ram
Принадлежит:

Disclosed are examples of systems, apparatus, methods and computer program products providing network security orchestration and management across different clouds. In some implementations, network security information includes a set of security policies indicating permitted communications between or among computing resources. The network security information is converted to a cloud-independent representation. From the cloud-independent representation, policy sets can be generated, where each policy set is specific to a different cloud. 1. A system comprising:a server system comprising one or more processors in communication with one or more memory devices, the server system configurable to cause:obtaining network security information comprising a set of security policies indicating permitted communications between or among computing resources,converting the network security information to a cloud-independent representation of the network security information,generating, from the cloud-independent representation, a plurality of policy sets, each policy set being specific to a respective one of a plurality of clouds of different cloud providers, andsending each cloud-specific policy set to the respective cloud.2. The system of claim 1 , the server system further configurable to cause:monitoring deployment of a cloud-specific policy set to a respective cloud, the monitoring comprising one or more of: obtaining deployment status information indicating success or an error in the deployment, obtaining resource status information indicating status of one or more computing resources in the respective cloud, detecting a change between the cloud-specific policy set and a different policy set deployed on the respective cloud, generating a notification message indicating the change, or sending to the respective cloud a request message that the change be reverted.3. The system of claim 1 , the server system further configurable to cause:verifying deployment of a cloud-specific ...

Подробнее
Номер записи: 46
27-02-2020 дата публикации

SYSTEM AND METHOD OF SUPERIMPOSING A THREE-DIMENSIONAL (3D) VIRTUAL GARMENT ON TO A REAL-TIME VIDEO OF A USER

Номер: US20200066052A1
Автор: Antonsen Christopher Paul, Kennedy John, Shah Syed Faisal
Принадлежит:

A system and a method for superimposing a garment onto an image or a real-time video of a user are disclosed. After a person captures an image or video of them self and after the person selects a garment that they wish to see them self virtually wearing, instructions executed by a processor may be used to overlay an image of the selected garment onto the image or video of the person. Images or a real-time video of the person may be captured from a reflection of the person in a mirror after which a computing device may generate a combined image of the person that depicts that person wearing a selected garment. Images of the garment overlaid over the captured images or video may show a user how the garment looks on their body from different angles or perspectives when they cannot physically touch the garment. 1. A method for generating images , the method comprising:receiving a selection of a garment;receiving an image of a user that has been reflected by a mirror;identifying at least two salient points of the body of the user;scaling a size of the garment to match a distance between the at least two salient points of the body of the user; andgenerating an image of the user that includes the selected garment scaled to the size that matches the distance between the at least two salient points.2. The method of claim 1 , further comprising:identifying a feature included in the received user image; anddisplaying the generate image of the user that includes the selected garment, the generated image including the feature identified in the received user image and including a display preference associated with the selected garment.3. The method of claim 1 , further comprising receiving an application program from a server claim 1 , the application program including program code associated with overlaying an image of the selected garment on the received image of the user.4. The method of claim 1 , further comprising receiving data associated with the garment claim 1 , the ...

Подробнее
Номер записи: 47
05-03-2020 дата публикации

Orally Dissolving Melatonin Formulation With Acidifying Agent That Renders Melatonin Soluble In Saliva

Номер: US20200069803A1
Автор: Corsino Patrick, HASSAN DANIEL, HASSAN FRED, SHAH Syed M.
Принадлежит:

A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva. 1. A composition comprising an oral thin film pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein , the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva , the dosage form being capable of completely disintegrating in the saliva within ten minutes from contacting the saliva.2. The composition of claim 1 , wherein the dosage form is 5% w/w to 20% w/w of the acid.3. The composition of claim 1 , wherein the therapeutically effective amount of melatonin is 0.2 mg to 20 mg.4. The composition of claim 1 , wherein the acid is a carboxylic acid.5. The composition of claim 1 , wherein the acid is citric acid.6. A method comprising administering a composition comprising an oral thin film pharmaceutical dosage form to a subject in need thereof claim 1 , the dosage form dissolving in the subject's saliva while maintaining a pH of 4 or less within the saliva during the time the dosage form is dissolving claim 1 , the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva claim 1 , the dosage form completely disintegrating in the saliva within ten minutes from contacting the saliva.7. The method of claim 6 , wherein the dosage form is 5% w/w to 20% w/w of the acid.8. The method of ...

Подробнее
Номер записи: 48
23-03-2017 дата публикации

Controlled-Release Compositions of Melatonin Combined with Sedative and/or Analgesic Ingredients

Номер: US20170079919A1
Автор: Diorio Christopher, HASSAN DANIEL, HASSAN FRED, SHAH Syed M.
Принадлежит:

Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients. 1. A composition comprising a pharmaceutical dosage form having:a solid core including a combination of melatonin and a GABA receptor agonist ingredient located together within a first acidified polymeric matrix;an expedited release portion including 5% to 50% of the GABA receptor agonist ingredient in the pharmaceutical dosage form, the expedited release portion being effective to release substantially all of the GABA receptor agonist ingredient therein within about 2 hours from placement in a 0.1 N HCl solution; anda sustained release portion including the remainder of the GABA receptor agonist ingredient in the pharmaceutical dosage form, the sustained release portion being effective to release substantially all of the GABA receptor agonist ingredient therein within about 10 hours from placement in a phosphate buffer with a pH of 6.8.2. The composition of claim 1 , wherein the first acidified polymeric matrix has a pH of about 1 to about 4.4.3. The composition of claim 1 , wherein the sustained release portion includes a plurality of individual granules that have the remainder of the GABA receptor agonist ingredient in the pharmaceutical dosage form therein.4. The composition of claim 1 , further comprising an analgesic ingredient in the expedited release portion.5. The composition of claim 1 , further comprising an analgesic ingredient in the expedited release portion; andwherein the sustained release portion includes a plurality of individual granules that have ...

Подробнее
Номер записи: 49
31-03-2022 дата публикации

TECHNIQUES FOR REFERENCE SIGNAL PATTERNS

Номер: US20220104223A1
Автор: Ma Liangping, RICO ALVARINO Alberto, Shah Syed Hashim Ali, Wang Xiao Feng
Принадлежит:

Methods, systems, and devices for wireless communications are described. A user equipment (UE) may receive a first indication of a set of reference signal instances within a set of resources. The UE may receive a second indication of a resource element format of a reference signal instance of the set of reference signal instances, the resource element format including one or more null resource elements and one or more reference signal resource elements. The UE may additionally receive, from a base station, a reference signal for estimating carrier frequency offset (CFO) based on the first indication of the set of reference signal instances and the second indication of the resource element format of the reference signal instance. The UE may then communicate with the base station based on receiving the reference signal. 1. An apparatus for wireless communication at a user equipment (UE) , comprising:a processor,memory coupled with the processor; and{'claim-text': ['receive a first indication of a set of reference signal instances within a set of resources;', 'receive a second indication of a resource element format of a reference signal instance of the set of reference signal instances, the resource element format comprising one or more null resource elements and one or more reference signal resource elements;', 'receive, from a base station, a reference signal for estimating carrier frequency offset based at least in part on the first indication of the set of reference signal instances and the second indication of the resource element format of the reference signal instance; and', 'communicate with the base station based at least in part on receiving the reference signal.'], '#text': 'instructions stored in the memory and operable, when executed by the processor, to cause the apparatus to:'}2. The apparatus of claim 1 , wherein the instructions are further executable by the processor to cause the apparatus to:receive, from the base station, a first control message ...

Подробнее
Номер записи: 50
19-06-2014 дата публикации

CONTROLLED-RELEASE MELATONIN COMPOSITIONS AND RELATED METHODS

Номер: US20140171478A1
Автор: HASSAN DANIEL, Shah Syed
Принадлежит: ZX PHARMA, LLC

A melatonin-containing product includes a composition comprising melatonin, a pH lowering agent, and a gel-forming forming polymer. When ingested, the composition forms an acidic aqueous gel matrix having melatonin dissolved therein for releasing melatonin into the intestines for a sustained time period. 1. A controlled-release melatonin-containing product comprising: 'said composition provides a first release dose of melatonin for assisting in inducement of sleep and a subsequent sustained release dose of melatonin for assisting in sustaining sleep.', 'a composition comprising melatonin, a pH lowering agent, and a gel-forming forming polymer that, when said composition is ingested, forms an aqueous gel matrix having melatonin dissolved therein and an internal pH of less than 4.4 in said aqueous gel matrix, wherein'}2. The product of claim 1 , wherein said composition is in tablet dosage form claim 1 , multiparticulate-containing dosage form claim 1 , or a combination thereof.3. The product of claim 1 , wherein said composition is effective to release approximately 50% of said melatonin in said composition into the gastrointestinal tract within approximately two hours after oral ingestion.4. The product of claim 3 , wherein said composition is effective to release substantially all of the remaining melatonin in said composition into the gastrointestinal tract over approximately three to approximately ten hours after oral ingestion.5. The product of claim 3 , wherein said composition is effective to release substantially all of the remaining melatonin in said composition into the lower gastrointestinal tract over approximately three to approximately ten hours after oral ingestion.6. The product of claim 1 , wherein said pH lowering agent is an acid claim 1 , acidic buffer claim 1 , or a combination thereof.7. The product of claim 1 , wherein said internal pH is 2 to 4 in said aqueous gel matrix.8. The product of claim 1 , wherein said composition further comprises at ...

Подробнее
Номер записи: 51
19-06-2014 дата публикации

MELATONIN TREATMENT METHODS

Номер: US20140171479A1
Автор: HASSAN DANIEL, Shah Syed
Принадлежит: ZX PHARMA, LLC

A method of treating a human subject in need of melatonin therapy comprises administering to a human subject a composition comprising melatonin dispersed in a polymer matrix adapted to cover the melatonin in a melatonin solubility enhancing pH environment after ingestion and to maintain the melatonin solubility enhancing pH environment when said composition is present in said subject's intestines so that an effective amount of melatonin is released into the subject's intestines. 1. A method of treating a human subject in need of melatonin therapy , the method comprising: ["said composition releases approximately 50% of the melatonin into said subject's gastrointestinal tract within approximately two hours after ingestion and releases substantially all of the remaining melatonin into said subject's gastrointestinal tract within approximately eight hours after ingestion, and", 'said melatonin solubility enhancing pH environment has a pH of 2-4., "administering to a human subject a composition comprising melatonin dispersed in a polymer matrix adapted to cover the melatonin in a melatonin solubility enhancing pH environment after ingestion and to maintain said melatonin solubility enhancing pH environment when said composition is present in said subject's intestines so that an effective amount of melatonin is released into said subject's intestines, wherein"}2. The method of claim 1 , wherein said subject is pre-identified as having a circadian rhythm disorder.3. The method of claim 1 , wherein said subject is pre-identified as having a melatonin deficiency.4. The method of claim 1 , wherein said pH of 2-4 is imparted to said composition with sufficient acid and/or acidic buffer in said composition to impart said pH.5. The method of claim 1 , wherein said pH of 2-4 is imparted to said composition with citric acid to impart said pH.6. The method of claim 1 , wherein said composition comprises at least one other active ingredient in addition to said melatonin.7. A method ...

Подробнее
Номер записи: 52
07-04-2016 дата публикации

Multiparticulate L-Menthol Formulations and Related Methods

Номер: US20160095822A1
Автор: Daniel Hassan, Fred Hassan, Sarah Hassan, Syed M. Shah
Принадлежит: ZxPharma LLC

A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.

Подробнее
Номер записи: 53
01-04-2021 дата публикации

MANGANESE OXIDE NANOPARTICLE CARBON MICROPARTICLE ELECTROCATALYST AND METHOD OF MAKING FROM ALBIZIA PROCERA LEAF

Номер: US20210095384A1
Автор: AZIZ Md. Abdul, SHAH Syed Shaheen, Yamani Zain Hassan
Принадлежит: KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS

A method for making an electrocatalyst containing manganese oxide nanoparticles present on carbon obtained from (MnONPs-C) for electrochemical water oxidation. The method includes a thermal decomposition and forms a product with specific morphological variations, including crystalline structure, elemental composition, and chemical compatibility. The manganese oxide nanoparticles are well dispersed over the carbon. The amount of manganese oxide nanoparticles increases by increasing the amount of precursor. Single-phase formation of the MnO, and MnOalong with MnO phase occurs at low and high amount of the precursor materials, respectively. The electrocatalyst can be used for the purpose electrolytic water splitting. 1: An electrocatalyst , comprising:manganese oxide nanoparticles supported on carbon microparticles,{'i': 'Albizia procera', 'wherein the manganese oxide nanoparticles are in the form of crystallites having an average diameter in the range of 5-25 nm, and the carbon microparticles are derived from leaves and have an average longest dimension in the range of 100-300 μm.'}2: The electrocatalyst of claim 1 , wherein the manganese oxide nanoparticles have an average longest dimension in the range of 10 nm to 15 nm.3: The electrocatalyst of claim 1 , wherein the thickness of the carbon microparticles is less than 10 μm.4: The electrocatalyst of claim 1 , wherein the manganese oxide nanoparticles have peaks in the XRD at 2(θ) Bragg angles of 37±1° and 42±1°.5: The electrocatalyst of claim 1 , wherein the Mn:C molar ratio is from 10:1 to 1:10.6: The electrocatalyst of claim 1 , wherein the Mn:C molar ratio is from 5:1 to 1:1.7: An electrode claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'sup': 2', '2, 'an electrically conductive substrate coated with the electrocatalyst of , wherein the electrode has a current density in the range of 6-18 mA/cmat 1.5 V and an over potential in the range of 800-900 mV at 5 mA/cmin 0.1 NaOH.'}8: The ...

Подробнее
Номер записи: 54
06-04-2017 дата публикации

ROLE-SPECIFIC DEVICE BEHAVIOR

Номер: US20170097827A1
Автор: Furtado Andre Wilson Brotto, Richardson Matthew, Rounthwaite Robert L., Shah Syed Fahad Allam, Sharma Shantanu, Shi Xiaohan, White Ryen
Принадлежит:

In many computing scenarios, an individual may interact with a device in a variety of roles, such as a student, an intern, and a gamer. While the individual may utilize the device in different ways for each role (e.g., using a particular set of files, applications, websites, and services), the device is not typically informed of the individual's role, and provides generalized device behavior irrespective of the individual's role. Presented herein are techniques for adapting device behavior based on the current role of the individual. Such techniques involve evaluating the individual's role determinants to identify and automatically select the individual's current role; selecting a current role profile, as a subset of the details of the individual profile that are associated with the current role, and excluding details that are not associated with the current role; and adjusting the device behavior according to the current role profile of the individual. 1. A device that exhibits a device behavior while interacting with an individual represented by an individual profile , the device comprising:a processor; and a current role selector that, responsive to detecting a role determinant of the individual, selects, among at least two roles of the individual, a current role that is associated with the role determinant;', 'a role profile selector that selects, from the individual profile, a current role profile comprising at least one selected individual profile detail that is associated with the current role, and excluding at least one individual profile detail that is not associated with the current role; and', 'a device behavior adjuster that adjusts the device behavior of the device according to the current role profile of the current role of the individual., 'a memory storing instructions that, when executed by the processor, provide2. The device of claim 1 , wherein:the device further comprises a user interface that enables interaction with the individual according to ...

Подробнее
Номер записи: 55
28-04-2016 дата публикации

PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF

Номер: US20160113923A1
Автор: Bazhina Nataliya, Donato, Fabian Steven R., III George Joseph, Lokhnauth John, Megati Sreenivasulu, Melucci Charles, Ofslager Christian, Patel Niketa, Radebaugh Galen, SHAH Syed M., Szeliga Jan, Zhang Huyi, Zhu Tianmin
Принадлежит:

The present invention provides a compound of formula I: 2. The composition of claim 1 , wherein the Brønsted acid is selected from the group consisting of a hydrogen halide claim 1 , a carboxylic acid claim 1 , a sulfonic acid claim 1 , a sulfuric acid claim 1 , and a phosphoric acid.3. The composition of claim 1 , wherein A is selected from the group consisting of chloride claim 1 , bromide claim 1 , iodide claim 1 , fluoride claim 1 , sulfate claim 1 , bisulfate claim 1 , tartrate claim 1 , nitrate claim 1 , citrate claim 1 , bitartrate claim 1 , carbonate claim 1 , phosphate claim 1 , malate claim 1 , maleate claim 1 , fumarate claim 1 , sulfonate claim 1 , methylsulfonate claim 1 , formate claim 1 , carboxylate claim 1 , methylsulfate claim 1 , trifluoroacetate claim 1 , and succinate.4. The composition of claim 3 , wherein A is bromide.5. The composition of claim 1 , wherein X is selected from the group consisting of chloride claim 1 , bromide claim 1 , iodide claim 1 , fluoride claim 1 , sulfate claim 1 , bisulfate claim 1 , tartrate claim 1 , nitrate claim 1 , citrate claim 1 , bitartrate claim 1 , carbonate claim 1 , phosphate claim 1 , malate claim 1 , maleate claim 1 , fumarate claim 1 , sulfonate claim 1 , methylsulfonate claim 1 , formate claim 1 , carboxylate claim 1 , methylsulfate claim 1 , trifluoroacetate claim 1 , and succinate.6. The composition of claim 5 , wherein X is bromide.7. The composition of claim 1 , wherein the composition contains tungsten in an amount of less than about 60 parts per billion.8. The composition of claim 1 , wherein the compound of formula III is provided in a solution.9. The composition of claim 8 , wherein the solution comprises about 8 mg of the compound of formula III in about 0.4 mL water.10. The composition of claim 8 , wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.12. The composition of claim 1 , wherein the package is selected from the group consisting of: a ...

Подробнее
Номер записи: 56
30-04-2015 дата публикации

Linearization of Radio Frequency Transceivers and Test Systems Through Dynamic Extraction of Complex Nonlinear Models Thereof

Номер: US20150118971A1
Автор: Behnke Christopher J., Shah Syed Jaffar, Zeidan Mohamad A.
Принадлежит:

Dynamic characterization of complex high-order nonlinearity in transmitter (TX) and receiver (RX) signal chains of transceiver systems can be efficiently and accurately performed. A loopback connection may be used to facilitate self-characterization. Appropriate RX and TX configuration settings may be developed to facilitate de-coupling of individual RX and TX nonlinearities from measured cascade nonlinearity. The system's high-order response to a two-tone signal generation may be measured, and complex mathematical analysis may be performed to identify and isolate passband nonlinear components to extract a high-order memory-less model for the system. The extracted system model may be used in the corrective and non-iterative pre-distortion of generated signals and in the post-distortion of received signals to improve linearity performance of the transceiver. The memory-less model and the analytical system are effective in improving performance of class-A-amplifier-based signal chains that are common in test and measurement systems and channel emulation systems. 1. A method for obtaining a complex high-order nonlinear model of a first signal path of a radio frequency (RF) system , the method comprising:adjusting the first signal path to operate according to specified settings;configuring a second signal path of the RF system to operate in a high-linearity mode;generating, in the first signal path, a test signal at a desired level;acquiring, by the second signal path, the generated test signal; andextracting, by a processing unit, a complex high-order nonlinear model representative of the first signal path, comprising analyzing, by the processing unit, the acquired test signal according to a specified algorithm.2. The method of claim 1 , wherein the first signal path is a complement of the second signal path.3. The method of claim 2 , wherein the first signal path is a transmit (TX) signal chain claim 2 , and the second signal path is a receive (RX) signal chain.4. The ...

Подробнее
Номер записи: 57
25-04-2019 дата публикации

ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE

Номер: US20190117645A1
Автор: AL SHAREFFI Kadum A., COHEN Jonathan Marc, DIORIO Christopher Richard, EHRNSPERGER Eric C., MENG Xu, SHAH Syed M.
Принадлежит: Wyeth, LLC

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. 1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide , and (ii) sodium dodecyl sulfate (SDS) , wherein the composition is a tablet , wherein methylnaltrexone bromide is the sole active agent , and wherein the composition comprises from about 7% to about 75% methylnaltrexone cation and dodecyl sulfate anion , based upon the total weight of the composition.2. The pharmaceutical composition of claim 1 , wherein the tablet is not enterically coated.3. The pharmaceutical composition of claim 2 , further comprising a rapid-acting disintegrant.4. The pharmaceutical composition of claim 3 , wherein the rapid-acting disintegrant is an effervescent disintegrant.5. The pharmaceutical composition of claim 3 , wherein the rapid-acting disintegrant is sodium bicarbonate.6. The pharmaceutical composition of claim 2 , wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.7. The pharmaceutical composition of claim 6 , wherein at least 75% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.8. The pharmaceutical composition of claim 2 , wherein at least 90% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.9. The pharmaceutical composition of claim 2 , wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.10. The pharmaceutical composition of claim 9 , wherein the solution is at a pH of about 1 to about 4.11. The pharmaceutical composition of claim 3 , wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl ...

Подробнее
Номер записи: 58
25-04-2019 дата публикации

ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE

Номер: US20190117646A1
Автор: AL SHAREFFI Kadum A., COHEN Jonathan Marc, DIORIO Christopher Richard, EHRNSPERGER Eric C., MENG Xu, SHAH Syed M.
Принадлежит: Wyeth, LLC

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. 1. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone bromide , and (ii) sodium dodecyl sulfate (SDS) , wherein the composition is a tablet , wherein methylnaltrexone bromide is the sole active agent , wherein the tablet is not enterically coated , and wherein at least 50% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.2. The pharmaceutical composition of claim 1 , further comprising a rapid-acting disintegrant.3. The pharmaceutical composition of claim 2 , wherein the rapid-acting disintegrant is an effervescent disintegrant.4. The pharmaceutical composition of claim 2 , wherein the rapid-acting disintegrant is sodium bicarbonate.5. The pharmaceutical composition of claim 1 , wherein at least 75% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.6. The pharmaceutical composition of claim 5 , wherein at least 90% of the composition dissolves in a dissolution apparatus with paddles at 100 rpm in 900 mL of 0.1 N HCl at 37° C. within about 15 minutes.7. The pharmaceutical composition of claim 1 , wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.8. The pharmaceutical composition of claim 7 , wherein the solution is at a pH of about 1 to about 4.9. The pharmaceutical composition of claim 2 , wherein an ion pair forms when the methylnaltrexone bromide and sodium dodecyl sulfate (SDS) are dissolved in solution.10. The pharmaceutical composition of claim 9 , wherein the solution is at a pH of about 1 to about 4.11. The pharmaceutical composition of claim 1 , wherein the composition in solution has an apparent octanol/water ...

Подробнее
Номер записи: 59
11-05-2017 дата публикации

Controlled-Release Melatonin Compositions and Related Methods

Номер: US20170128419A1
Автор: HASSAN DANIEL, SHAH Syed M.
Принадлежит:

An oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin includes melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin. The dosage form is effective to release melatonin therefrom for at least six hours after oral ingestion. 1. A composition comprising:an oral melatonin pharmaceutical dosage form that contains a sustained release dose of melatonin;the dosage form including melatonin and an acid dispersed in a hydrogel-forming polymer matrix that combine after ingestion to form an acidic hydrogel containing the melatonin; andwherein the dosage form is effective to release melatonin therefrom for at least six hours after oral ingestion.2. The composition of claim 1 , wherein the dosage form is effective to release approximately 50% of the melatonin in the dosage form within approximately two hours after oral ingestion.3. The composition of claim 1 , wherein the dosage form is effective to release substantially all of the melatonin therein within ten hours after oral ingestion.4. The composition of claim 1 , wherein the amount of the acid is sufficient to impart a pH of less than 4.4 to the acidic hydrogel.5. The composition of claim 1 , wherein the amount of the acid is sufficient to impart a pH of 2-4 to the acidic hydrogel.6. The composition of claim 1 , wherein the dosage form further comprises at least one other active ingredient in addition to the melatonin.7. The composition of claim 1 , wherein the effective amount includes 5 micrograms to 10 milligrams of melatonin.8. The composition of claim 1 , wherein the effective amount includes about 2 milligrams of melatonin.9. The method of claim 1 , wherein the hydrogel-forming polymer matrix includes a cellulosic polymer.10. The composition of claim 1 , wherein the dosage form is a compressed tablet.11. The composition of claim 1 , wherein the each of the melatonin claim 1 , acid ...

Подробнее
Номер записи: 60
23-04-2020 дата публикации

ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE

Номер: US20200121673A1
Автор: AL SHAREFFI Kadum A., COHEN Jonathan Marc, DIORIO Christopher Richard, EHRNSPERGER Eric C., MENG Xu, SHAH Syed M.
Принадлежит: Wyeth, LLC

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. 125-. (canceled)26. A pharmaceutical composition for oral administration comprising a solid dosage of (i) methylnaltrexone , or a pharmaceutically acceptable salt thereof , (ii) an amphiphilic pharmaceutically acceptable excipient , (iii) a chelating agent , and (iv) a disintegrant.27. The pharmaceutical composition of claim 26 , wherein the methylnaltrexone claim 26 , or a pharmaceutically acceptable salt thereof claim 26 , is (R)—N-methylnaltrexone bromide.28. The pharmaceutical composition of claim 27 , wherein the (R)—N-methylnaltrexone bromide is present at about 150 mg.29. The pharmaceutical composition of claim 26 , wherein the chelating agent is EDTA or a salt thereof.30. The pharmaceutical composition of claim 29 , wherein the chelating agent comprises edetate calcium disodium.31. The pharmaceutical composition of claim 26 , wherein the disintegrant comprises a rapid acting disintegrant.32. The pharmaceutical composition of claim 31 , wherein the disintegrant comprises an effervescent disintegrant.33. The pharmaceutical composition of claim 26 , wherein the disintegrant comprises a combination of crospovidone and cross-linked sodium carboxymethyl cellulose.34. The pharmaceutical composition of claim 26 , wherein the composition is a tablet.35. The pharmaceutical composition of claim 34 , wherein the tablet is not enterically coated.36. The pharmaceutical composition of claim 27 , wherein (R)—N-methylnaltrexone bromide is the sole active agent.37. The pharmaceutical composition of claim 27 , wherein the amphiphilic pharmaceutically acceptable excipient is sodium dodecyl sulfate.38. The pharmaceutical composition of claim 37 , wherein the ratio of (R)—N-methylnaltrexone bromide to sodium dodecyl sulphate is about 3:1 by weight.39. The pharmaceutical composition of claim 26 , further comprising a binder. ...

Подробнее
Номер записи: 61
21-05-2015 дата публикации

TIGECYCLINE COMPOSITIONS AND METHODS OF PREPARATION

Номер: US20150141379A1
Автор: Fawzi Mahdi B., SHAH Syed M., Zhu Tianmin
Принадлежит:

The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer. 166-. (canceled)67. A composition consisting of tigecycline , lactose , and an acid , wherein the molar ratio of tigecycline to lactose is between about 1:1.6 to about 1:3.3 , and the pH of the composition in a solution is between about 4.0 and about 5.0 , wherein the acid is hydrochloric acid , and the composition further comprises tigecycline epimer in an amount that is not more than 2.56% as measured after storage of the composition at about 40° C. and 75% relative humidity for not more 39 days.68. The composition of claim 67 , wherein the composition is lyophilized.69. The composition according to further comprising a pharmaceutically acceptable diluent.70. The composition according to claim 69 , wherein the pharmaceutically acceptable diluent is water claim 69 , a saline claim 69 , Lactated Ringer's Injection solution claim 69 , or dextrose solution.71. The composition of claim 67 , wherein the pH of the composition in a solution is between 4.2 and about 4.8.72. A composition prepared in accord with a process comprising combining lactose with tigecycline and water to form a solution; reducing the pH of the solution with hydrochloric acid to between about 4.0 and about 5.0; and lyophilizing the solution to dryness to prepare a lyophilized composition;wherein the lactose is capable of reducing epimer formation of tigecycline whereby the lyophilized composition further comprises tigecycline epimer in an amount that is not more than 2.56% as measured after storage of the lyophilized composition at about 40° C. and 75% relative humidity for not more 39 days, and the molar ratio of tigecycline to lactose is between about 1:1.6 to about 1:3.3.73. The composition of further comprising combining the composition with a ...

Подробнее
Номер записи: 62
07-08-2014 дата публикации

SYNTHESIS AND BIOLOGICAL STUDIES OF AN ISOMERIC MIXTURE OF (E/Z) ISOXYLITONES AND ITS ANALOGUES

Номер: US20140221682A1
Автор: Ashraf Muhammad Nadeem, Choudhary M. Iqbal, Kahn Noureen, Malhi Saima Mahmood, Rahman Atta-ur, Shah Syed Uzair Ali, Shaheen Farzana, Simjee Shabana Usman
Принадлежит:

The invention relates to an anti-epileptic isoxylitone, 2,2′-(3,5,5-Trimethyl-2-cyclohexen-1-ylidene) acetic acid. 12-. (canceled)3. A method of treatment for epilepsy or epileptic seizures comprising administering an effective amount of isoxylitone 2 ,2′-(3 ,5 ,5-Trimethyl-2-cyclohexen-1-ylidene) acetic acid or an isomer , an acid analogue , a salt or a solvate thereof to an animal or human in need thereof.4. A method of treatment for reducing the level of c-Fos expression comprising administering an effective amount of isoxylitone 2 ,2′-(3 ,5 ,5-Trimethyl-2-cyclohexen-1-ylidene) acetic acid or an isomer , an acid analogue , a salt or a solvate thereof to an animal or human in need thereof.5. A method of treatment for reducing the level BNDF protein expression comprising administering an effective amount of isoxylitone 2 ,2′-(3 ,5 ,5-Trimethyl-2-cyclohexen-1-ylidene) acetic acid or an isomer , an acid analogue , a salt or a solvate thereof to an animal or human in need thereof.65. The method of any one of - claims 3 , wherein the isoxylitone further comprises a suitable physiological carrier. Epilepsy is a major neurological disorder globally, with high prevalence in developing world. About 30% of the epileptic population has seizures that are not responsive to presently available medical therapies. 90% of the people with epilepsy are found in developing regions. The currently available antiepileptic drugs are generally synthetic in nature. Despite many available chemotherapeutic agents, none are capable of controlling the seizures completely and most drugs have severe side-effects. In view of the large percentage of uncontrolled epileptics and the side effects experienced by patients with the existing medications, there is an urgent need for more selective and less toxic anticonvulsant drugs.Recent studies in our laboratory have led to the discovery of potent anticonvulsant agents, isoxylitones A and B from a medicinal plant Wall. Bioassay-guided isolation studies ...

Подробнее
Номер записи: 63
26-05-2016 дата публикации

TIGECYCLINE COMPOSITIONS AND METHODS OF PREPARATION

Номер: US20160144036A1
Автор: Fawzi Mahdi B., SHAH Syed M., Zhu Tianmin
Принадлежит: WYETH LLC

The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer. 175-. (canceled)76. A composition consisting essentially of tigecycline , a carbohydrate , and an acid , wherein the molar ratio of tigecycline to lactose is between about 1:1.6 to about 1:3.3 , and the pH of the composition in a solution is between about 4.0 and about 5.0 , wherein the acid is hydrochloric acid , and the composition further comprises tigecycline epimer in an amount that is not more than 2.56% as measured after storage of the composition at about 40° C. and 75% relative humidity for not more 39 days.77. The composition of claim 76 , wherein the composition is lyophilized.78. The composition according to further comprising a pharmaceutically acceptable diluent.79. The composition according to claim 78 , wherein the pharmaceutically acceptable diluent is water claim 78 , a saline claim 78 , Lactated Ringer's Injection solution claim 78 , or dextrose solution.80. The composition of claim 76 , wherein the pH of the composition in a solution is between 4.2 and about 4.8.81. The composition of claim 76 , wherein the carbohydrate is lactose.82. A composition prepared in accord with a process comprising combining lactose with tigecycline and water to form a solution; reducing the pH of the solution with hydrochloric acid to between about 4.0 and about 5.0; and lyophilizing the solution to dryness to prepare a lyophilized composition;wherein the lactose is capable of reducing epimer formation of tigecycline whereby the lyophilized composition further comprises tigecycline epimer in an amount that is not more than 2.56% as measured after storage of the lyophilized composition at about 40° C. and 75% relative humidity for not more 39 days, and the molar ratio of tigecycline to lactose is between about 1:1.6 ...

Подробнее
Номер записи: 64
28-05-2015 дата публикации

Synthesis and biological studies of an isomeric mixture of (e/z) isoxylitones and its analogues

Номер: US20150148417A1
Автор: Atta-ur- Rahman, Farzana Shaheen, M. Iqbal Choudhary, Muhammad Nadeem Ashraf, Noureen Kahn, Saima Mahmood Malhi, Shabana Usman Simjee, Syed Uzair Ali Shah
Принадлежит: Individual

The invention relates to an anti-epileptic isoxylitone, 2,2′-(3,5,5-Trimethyl-2-cylohexen-1-ylidene)acetic acid.

Подробнее
Номер записи: 65
04-06-2015 дата публикации

PERIPHERAL OPIOID RECEPTOR ANTAGONISTS AND USES THEREOF

Номер: US20150150866A1
Автор: Bazhina Nataliya, Donato, Fabian Steven R., III George Joseph, Lokhnauth John, Megati Sreenivasulu, Melucci Charles, Ofslager Christian, Patel Niketa, Radebaugh Galen, SHAH Syed M., Szeliga Jan, Zhang Huyi, Zhu Tianmin
Принадлежит:

The present invention provides a compound of formula I: 146-. (canceled)48. The composition of claim 47 , wherein the Brønsted acid is selected from the group consisting of a hydrogen halide claim 47 , a carboxylic acid claim 47 , a sulfonic acid claim 47 , a sulfuric acid claim 47 , and a phosphoric acid.49. The composition of claim 47 , wherein X or A is selected from the group consisting of chloride claim 47 , bromide claim 47 , iodide claim 47 , fluoride claim 47 , sulfate claim 47 , bisulfate claim 47 , tartrate claim 47 , nitrate claim 47 , citrate claim 47 , bitartrate claim 47 , carbonate claim 47 , phosphate claim 47 , malate claim 47 , maleate claim 47 , fumarate claim 47 , sulfonate claim 47 , methylsulfonate claim 47 , formate claim 47 , carboxylate claim 47 , methylsulfate claim 47 , trifluoroacetate claim 47 , and succinate.50. The composition of claim 49 , wherein X or A is bromide.51. The composition of claim 47 , wherein the tungsten is present in an amount of less than about 60 parts per billion.52. The composition of claim 47 , wherein the compound of formula III is provided in a solution.53. The composition of claim 47 , wherein the solution comprises about 8 mg of the compound of formula III in about 0.4 mL water.55. The composition of claim 47 , wherein the solution comprises about 12 mg of the compound of formula III in about 0.6 mL water.57. The composition of claim 47 , wherein the compound of formula III is contained within a package that is substantially free of tungsten.58. The composition of claim 57 , wherein the package is selected from the group consisting of a syringe claim 57 , a vial claim 57 , and an ampoule.59. The composition of claim 58 , wherein the package is a syringe.60. A method for treating a gastrointestinal disorder in a subject comprising administering the composition of .61. The method of claim 60 , wherein the gastrointestinal disorder is constipation.62. The method of claim 61 , wherein the constipation is opioid- ...

Подробнее
Номер записи: 66
24-05-2018 дата публикации

Closed-loop adaptive controls from cycle-to-cycle for injection rate shaping

Номер: US20180142638A1
Автор: Syed Shah Jalel
Принадлежит: Cummins Inc

The present disclosure provides a system for adjusting a fuel injector drive signal during a fuel injection event wherein the system comprises an engine having a fuel injector, a fuel control module configured to generate control signals corresponding to a desired fueling profile of a fuel injection event, and a fueling profile interface module that outputs drive profile signals to the fuel injector in response to the control signals to cause the fuel injector to deliver an actual fueling profile, wherein the fueling profile interface module changes the drive profile signals during the fuel injection event in response to a parameter signal indicating a characteristic of the actual fueling profile.

Подробнее
Номер записи: 67
14-08-2014 дата публикации

DRY POWDER COMPOUND FORMULATIONS AND USES THEREOF

Номер: US20140228389A1
Автор: Ofslager Christian, SHAH Syed M.
Принадлежит: Wyeth, LLC

The present invention provides lyophilized formulations comprising methylnaltrexone, and processes for preparation of provided formulations. Additionally provided are compositions and products containing the methylnaltrexone formulation, as well as methods for producing formulations, compositions and products. Provided formulations as well as compositions and products containing methylnaltrexone formulations are useful for preventing, treating delaying, diminishing or reducing the severity and/or incidence of side effects resulting from administration of analgesic opioids. 1. An amorphous dry powder formulation consisting essentially of methylnaltrexone , or a pharmaceutically acceptable salt thereof , and a filler.2. The formulation of claim 1 , wherein the methylnaltrexone is methylnaltrexone bromide.3. The formulation of claim 1 , wherein the filler is selected from the group consisting of a lactose claim 1 , mannitol claim 1 , and dextran.4. The formulation of claim 3 , wherein the filler is a lactose and the methylnaltrexone is methylnaltrexone bromide.5. The formulation of claim 4 , wherein the lactose is lactose monohydrate.6. The formulation of claim 1 , consisting essentially of:about 5 to about 500 mg of methylnaltrexone bromide; andlactose monohydrate.7. The formulation of claim 1 , wherein the methylnaltrexone and filler are present in approximately equal amounts by weight.8. The formulation of claim 1 , wherein the methylnaltrexone and filler are present in a ratio within the range of about 1:1 to about 1:5 by weight.9. A solution consisting essentially of water and the formulation of .10. The solution of claim 9 , wherein the lactose is lactose monohydrate.11. The solution of claim 10 , wherein the methylnaltrexone bromide and lactose monohydrate are present in approximately equal amounts by weight.12. The solution of claim 11 , wherein methylnaltrexone bromide is present in a concentration of about 0.5 mg/mL to about 25 mg/mL.13. A method of producing ...

Подробнее
Номер записи: 68
22-09-2022 дата публикации

SWITCH WITH VIRTUAL CHANNELS FOR SOFT LOCKING IN A NETWORK-ON-CHIP (NoC)

Номер: US20220303224A1
Автор: Benoit de Lescure, John CODDINGTON, Sanjay Despande, Syed Ijlal Ali SHAH
Принадлежит: Arteris Inc

A system and method for soft locking for a networking device in a network, such as a network-on-chip (NoC). Once a soft lock is established, the port and packet are given transmitting priority so long has the port has an available packet or packet parts that can make forward progress in the network. When the soft lock port's packet parts are not available, the networking device may choose another port and/or another packet. Any arbitration scheme may be used. Once the packet (or all the packet parts) has completed transmission, the soft lock is released.

Подробнее
Номер записи: 69
04-09-2014 дата публикации

Oral formulations and lipophilic salts of methylnaltrexone

Номер: US20140249171A1
Автор: Christopher Richard Diorio, Eric C. Ehrnsperger, Jonathan Marc Cohen, Kadum A. Al Shareffi, Syed M. Shah, Xu Meng
Принадлежит: WYETH LLC

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

Подробнее
Номер записи: 70
21-05-2020 дата публикации

IMAGE SIZE TRIGGERED CLARIFICATION TO MAINTAIN IMAGE SHARPNESS

Номер: US20200159016A1
Автор: CABANIER Henricus, IDRIS SHAH Syed
Принадлежит: Magic Leap, Inc.

An application engine renders an image based on image data from a content source. A display engine displays the image to a user. The image is adjustable from a first size to a second size. A detection system detects the size adjustment. An application executes a clarification routine to maintain sharpness of the image. 1. A viewing system comprising:a content source to hold image data;an application engine, forming part of an application, communicatively connected to the content source to receive the image data and render an image based on the image data;a display engine communicatively connected to the application engine to display the image to a user, the image having a first size, the image being adjustable to a second size that is smaller than the first size; anda detection system that detects a measure indicative of adjustment of the image from the first size to the second size, wherein the application, in response to the detection, executes a clarification routine to maintain sharpness of the image.2. The viewing system of claim 1 , wherein the display engine displays the image to a user at a first virtual distance relative to the user and the image having the first size claim 1 , the image being movable to a second virtual distance relative to the user and the image having a second size that is smaller than the first size claim 1 , and the detection system is a movement detection system that detects movement of the image to the second virtual distance relative to the user.3. The viewing system of claim 2 , wherein the application includes:a frame size determinator that determines a select frame size that corresponds to the second virtual distance, the clarification routing being based on the frame size.4. The viewing system of claim 3 , wherein the application includes:a look-up table having a plurality of distances and a plurality of frame sizes corresponding to the respective distances; anda look-up algorithm that determines a select distance from the look- ...

Подробнее
Номер записи: 71
25-06-2015 дата публикации

Providing a Sensor Composite Service Based on Operational and Spatial Constraints

Номер: US20150180986A1
Автор: Bisdikian Chatschik, Gibson Christopher R., HARRIES DOMINIC P., Shah Syed Y., Zerfos Petros
Принадлежит: INTERNATIONAL BUSINESS MACHINES CORPORATION

Mechanisms are provided for generating a composite service. A request to generate the composite service is received that identifies a geospatial region of interest for the composite service. One or more types of components needed to generate the composite service are determined and, for each component of a plurality of components of the one or more types of components, a corresponding spatial coverage characteristic is determined. A subset of components, from the plurality of components, is selected based on the spatial coverage characteristics of the plurality of components and the geospatial region of interest. The composite service is then generated based on the selected subset of components from the plurality of components. 1. A method , in a data processing system comprising a processor and a memory , for generating a composite service , the method comprising:receiving, by the data processing system, a request to generate the composite service, wherein the request identifies a geospatial region of interest for the composite service;determining, by the data processing system, one or more types of components needed to generate the composite service;determining, by the data processing system, for each component of a plurality of components of the one or more types of components, a corresponding spatial coverage characteristic;selecting, by the data processing system, a subset of components from the plurality of components based on the spatial coverage characteristics of the plurality of components and the geospatial region of interest; andgenerating the composite service based on the selected subset of components from the plurality of components.2. The method of claim 1 , wherein the composite service is a sensor composite service and the plurality of components comprises at least one sensor providing sensor data for processing and at least one primitive sensor service that processes the sensor data provided by the at least one sensor.3. The method of claim 1 , ...

Подробнее
Номер записи: 72
02-07-2015 дата публикации

High-frequency electrical nerve block

Номер: US20150182749A1
Автор: Jon J. SNYDER, Nemath Syed Shah, Zi-Ping Fang
Принадлежит: Neuros Medical Inc

A method and apparatus that resulted in blocking an action potential in a nerve.

Подробнее
Номер записи: 73
28-05-2020 дата публикации

Controlled-Release Compositions of Melatonin Combined with Sedative and/or Analgesic Ingredients

Номер: US20200163886A1
Автор: Diorio Christopher, HASSAN DANIEL, HASSAN FRED, SHAH Syed M.
Принадлежит:

Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients. 1. A composition comprising an oral pharmaceutical dosage form comprising:a solid core including a combination of melatonin and a GABA receptor agonist ingredient located together within a first acidified polymeric matrix;an expedited release portion including a first portion of the GABA receptor agonist ingredient in the pharmaceutical dosage form, the expedited release portion being effective to release substantially all of the GABA receptor agonist ingredient therein within about 2 hours from placement in a 0.1 N HCl solution; anda sustained release portion including a second portion of the GABA receptor agonist ingredient in the pharmaceutical dosage form, the sustained release portion being effective to release substantially all of the GABA receptor agonist ingredient therein from at least 5 to about 8 hours from placement in a phosphate buffer with a pH of 6.8.2. The composition of claim 1 , wherein the first acidified polymeric matrix has a pH of about 1 to about 4.4.3. The composition of claim 1 , wherein the sustained release portion includes a plurality of individual granules that have the remainder of the GABA receptor agonist ingredient in the pharmaceutical dosage form therein.4. The composition of claim 1 , further comprising an analgesic ingredient in the expedited release portion.5. The composition of claim 1 , further comprising an analgesic ingredient in the expedited release portion; andwherein the sustained release portion includes a plurality of ...

Подробнее
Номер записи: 74
08-07-2021 дата публикации

ORAL SOLID CANNABINOID OIL COMPOSITION FOR TREATING GASTROINTESTINAL DISORDERS

Номер: US20210205235A1
Автор: HASSAN FRED, SHAH Syed M.
Принадлежит:

Cannabinoid oil compositions may be used to treat gastrointestinal disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core. 1. A composition comprising:an oral multiparticulate dosage form including a plurality of individual particulates, the individual particulates comprising:(a) a solid core including an effective amount of cannabinoid oil bound in microcrystalline cellulose; and(b) an enteric coating over the solid core.2. The composition of claim 1 , wherein the individual particulates are spheroidal claim 1 , have an average diameter of 0.5 mm to 1.7 mm claim 1 , and further comprise an enteric coating material and a disintegrant combination that cause the individual particulates to release most of the cannabinoid oil in a subject's duodenum for treating inflammation of the duodenum.3. The composition of claim 1 , wherein the individual particulates are spheroidal claim 1 , have an average diameter of 0.5 to 1.7 mm claim 1 , and are configured to release most of the cannabinoid oil in a jejunum for treating inflammation of the jejunum.4. The composition of claim 1 , wherein the individual particulates are spheroidal claim 1 , have an average diameter of 0.5 to 1.7 mm claim 1 , and are configured to release most of the cannabinoid oil in an ileum for treating inflammation of the ileum.5. The composition of claim 1 , wherein the individual particulates are spheroidal claim 1 , have an average diameter of 1.8 to 3 mm claim 1 , and the dosage form is configured to release the cannabinoid oil for at least 6 hours throughout a subject's intestines.6. The composition of claim 1 , wherein the cannabinoid oil is bound in microcrystalline cellulose by being stored within microcrystalline cellulose's fibrous network.7. The composition of claim 1 , ...

Подробнее
Номер записи: 75
13-06-2019 дата публикации

NETWORK INFRASTRUCTURE OPTIMIZATION PLATFORM

Номер: US20190180335A1
Автор: Banerjee Sumit, DELANEY Sean, Goekbora Bora, Mckeever Natalie H., Saiget Scott, Shah Syed Feroze H., Steger Terry Wayne
Принадлежит:

Implementations are directed to receiving, by a NIO platform, one or more sets of data, the one or more sets of data including a set of historical data, and a set of opportunity data, processing, by the NIO platform, at least the set of historical data to determine a sub-set of data, the sub-set of data including data types having a relatively high impact on network infrastructure cost, providing, by the NIO platform, respective cost estimations for two or more network infrastructure opportunities by processing the set of opportunity data using a cost model provided from the sub-set of data, prioritizing, by the NIO platform, two or more network infrastructure opportunities relative to each other, and transmitting, by the NIO platform, one or more visualizations for display to a user on a computing device, the one or more visualizations graphically depicting prioritization of the two or more network infrastructure opportunities. 1. A computer-implemented method for network infrastructure optimization (NIO) , the method being executed by one or more processors and comprising: 'the one or more sets of data comprising a set of historical data, and a set of opportunity data;', 'one or more sets of data,'}, 'receiving, by a NIO platform executed by the one or more processors 'the sub-set of data comprising data types having a relatively high impact on network infrastructure cost;', 'processing, by the NIO platform, at least the set of historical data to determine a sub-set of data,'} 'the providing performed by processing the set of opportunity data using a cost model provided from the sub-set of data;', 'providing, by the NIO platform, respective cost estimations for two or more network infrastructure opportunities,'}prioritizing, by the NIO platform, two or more network infrastructure opportunities relative to each other; and 'the one or more visualizations graphically depicting prioritization of the two or more network infrastructure opportunities.', 'transmitting, by ...

Подробнее
Номер записи: 76
05-07-2018 дата публикации

PNEUMATIC DEVICE FOR ACTUATING ORGANS

Номер: US20180185173A1
Автор: Cianchetti Matteo, Dario Paolo, Laschi Cecilia, Mazzolai Barbara, SHAH Syed Taimoor Hassan
Принадлежит:

The device () takes up the basic structure and operation of the McKibben type artificial muscles and similar, in which is provided a hollow cylindrical chamber (), of resilient material, which is inflated in the active phase (K). The chamber () interacts with a braided sleeve (), consisting of threads (), almost inextensible, arranged in crossed helical paths having a characteristic angle of inclination β with respect to the longitudinal axis (X) of the device (). The sleeve () is connected at the ends with two rigid head members (A, B) provided to be mechanically connected to external bodies. The invention provides adjusting means (), associated to said rigid head members (A, B) adapted to vary their distance (D) at rest, so as to require a proportional and consistent change in the angle of inclination β: if the latter is exactly 54.7°, the device (), in the active phase (K) stiffens without dimensional changes, if the angle β is greater an axial extension is obtained, if the angle β is smaller an axial contraction is obtained. 110-. (canceled)11. A pneumatic actuating device for the actuation of organs , comprising:a chamber, wherein the chamber is an airtight, hollow cylindrical member made of an elastomeric material and is adapted to be pressurized with air or other fluid;a sleeve, wherein the sleeve is braided, wherein the sleeve is disposed coaxially outside the chamber and constituted by a first series of flexible and substantially inextensible threads, arranged each according to its own helical path of the same diameter and helix angle but different start points, and by a second series of identical flexible and substantially inextensible threads, arranged according to respective helical paths symmetrical to those of the above mentioned first series, with the first and second set of flexible threads adapted to form the meshes of the sleeve, in which each of the helical paths is inclined with a same predetermined angle with respect to the longitudinal axis of ...

Подробнее
Номер записи: 77
13-06-2019 дата публикации

PARTIALLY DISJOINT EQUALIZATION AND CARRIER RECOVERY

Номер: US20190182082A1
Автор: "Abughalieh Nashat", Ali Shah Syed Faisal, Li Chuandong
Принадлежит: Huawei Technologies Co., Ltd.

An apparatus in a signal receiver, such as an optical signal receiver, is provided. An adaptive equalizer provides an equalized output indicative of a received signal. A feedback component receives the equalized output and provides feedback to the adaptive equalizer. A carrier recovery component receives the equalized output from the adaptive equalizer provides estimates of symbols. The carrier recovery component is partially or fully disjoint from the feedback component, thus removing the carrier recovery component from equalizer the feedback loop. The feedback component can include an initial carrier recovery component and a phase rotation and detection component. The initial carrier recovery component generates a carrier recovery output based on the equalized output. The phase rotation and detection component performs a phase rotation based on the carrier recovery output. 1. An apparatus in a signal receiver , the apparatus comprising:an adaptive equalizer configured to receive an input indicative of a received signal and to provide an equalized output indicative of a corrected version of the received signal;a feedback component configured to receive the equalized output from the adaptive equalizer and provide feedback to the adaptive equalizer based on the equalized output; anda fine carrier recovery component configured to directly or indirectly receive the equalized output from the adaptive equalizer and to provide estimates of symbols carried in the received signal based on the equalized output, wherein the fine carrier recovery component is partially or fully disjoint from the feedback component.2. The apparatus of claim 1 , wherein the feedback component and the fine carrier recovery component operate in parallel with each other claim 1 , and wherein at least a portion of data generated by the feedback component is provided to the fine carrier recovery component claim 1 , at least a portion of data generated by the fine carrier recovery component is ...

Подробнее
Номер записи: 78
11-06-2020 дата публикации

FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF

Номер: US20200179270A1
Автор: Bazhina Nataliya, Fawzi Mahdi B., Ofslager Christian, SHAH Syed M.
Принадлежит: Wyeth, LLC

The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids. 138-. (canceled)39. A method of preparing a methylnaltrexone formulation for parenteral administration , the method comprising the steps of:preparing a solution comprising methylnaltrexone or a pharmaceutically acceptable salt thereof, an isotonic agent and a calcium salt chelating agent; andsterilizing the resulting solution and distributing to one or more sealed containers.40. The method of claim 39 , wherein the calcium salt chelating agent is selected from the group calcium ethylenediaminetetraacetic acid (EDTA) claim 39 , calcium diethylenetriaminepentaacetic acid (DTPA) claim 39 , calcium hydroxyethylenediaminetriacetic acid (HEDTA) claim 39 , calcium ethylene glycol-bis-(2-aminoethyl)-N claim 39 ,N claim 39 ,N′ claim 39 ,N′-tetraacetic acid (EGTA) claim 39 , calcium nitrilotriacetic acid (NTA) claim 39 , calcium citrate claim 39 , and calcium salt derivatives thereof.41. The method of wherein the active compound is methylnaltrexone bromide.42. The method of claim 39 , wherein the solution comprises an isotonic agent.43. The method of wherein the isotonic agent is selected from the group consisting of sodium chloride claim 42 , mannitol claim 42 , lactose claim 42 , dextrose claim 42 , glycerol claim 42 , and sorbitol.44. The method of claim 43 , wherein the isotonic agent comprises a delivery vehicle selected from the group consisting of 5% Dextrose claim 43 , Lactated Ringer's Injection and 0.65% NaCl and 0.9% NaCl.45. The method of claim 39 , wherein the solution comprises water for injection.46. The method of claim 39 , wherein the calcium salt chelating agent is calcium ethylenediaminetriacetic acid (EDTA) or calcium ethylene glycol-bis-(2-aminoethyl)-N claim 39 ,N claim 39 ,N′ claim ...

Подробнее
Номер записи: 79
22-07-2021 дата публикации

DOSAGE FORM WITH SUSTAINED RELEASE MELATONIN PELLETS

Номер: US20210220264A1
Автор: HASSAN DANIEL, SHAH Syed M.
Принадлежит:

A composition comprises a therapeutically effective oral pharmaceutical dosage form. The dosage form includes an aqueous carrier material having an acidic pH and a plurality of individual pellets having a first dose of melatonin therein. The individual pellets comprises (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating. A dissolution pH of the enteric coating is higher than the acidic pH of the aqueous carrier material. 1. A composition comprising a therapeutically effective oral pharmaceutical dosage form comprising:(a) an aqueous carrier material having an acidic pH;(b) a plurality of individual pellets having a first dose of melatonin therein, the individual pellets comprising (i) a solid core; (ii) an active coating over the solid core, the active coating including melatonin and a hydrophilic binder; and (iii) an enteric coating over the active coating, a dissolution pH of the enteric coating being higher than the acidic pH of the aqueous carrier material.2. The composition of claim 1 , wherein the melatonin is a powder having a median melatonin particle size of 5 μm to 40 μm.3. The composition of claim 1 , wherein the aqueous carrier material includes a second dose of melatonin therein and dosage form releases the second dose of melatonin into the subject's oral cavity and stomach.4. The composition of claim 1 , wherein the dosage form is a beverage and the aqueous carrier material includes water.5. The composition of claim 1 , wherein the dosage form is a gummy and the aqueous carrier material is a gummy gelling agent.6. The composition of claim 1 , wherein:the individual pellets further comprise a separation coating over the active coating, a subcoat between over the separation coating, and enteric coating over the subcoat;the subcoat includes a hydrogel-forming polymer and an acid, the acid imparting a pH of 0.1 to 4.4 to the ...

Подробнее
Номер записи: 80
22-07-2021 дата публикации

APPARATUSES AND METHODS FOR ADJUSTING A THERAPEUTIC ELECTRICAL DOSE

Номер: US20210220642A1
Автор: Fang Zi-Ping, IORIO Matthew J., SYED SHAH Nemath
Принадлежит: Neuros Medical, Inc.

Apparatuses and methods of using them for setting a therapeutic dose of a neuromodulator implanted into a patient are described. The methods and apparatuses described herein may include determining the dose based on a patient-specific database of previously delivered dose parameters and corresponding pre-delivery and post-delivery pain estimates from the patient. 1. A system for treating a patient's pain using high-frequency nerve block , the system comprising: one or more electrodes configured to apply high-frequency neural modulation to one or more nerves; and', 'a controller configured to apply a treatment dose having a set of treatment dose parameters from the one or more electrodes; and, 'an implantable neuromodulator comprising one or more processors;', 'a patient-specific dosing database of previously delivered doses and corresponding estimates of a change in patient-reported pain levels from before and after delivery of each dose; and', ["updating the patient-specific dosing database with the pre-delivery pain estimate from the patient, the post-delivery pain estimate from the patient, the set of treatment dose parameters corresponding to the pre-delivery pain estimate and the post-delivery pain estimate, and any adjustments made to the treatment dose parameters by the patient or the patient's caregiver during delivery; and", 'generating the set of treatment dose parameters based on the patient-specific database., 'a memory coupled to the one or more processors, the memory configured to store computer-program instructions, that, when executed by the one or more processors, perform a computer-implemented method comprising], 'a dose selector comprising2. The system of claim 1 , further comprising a user interface configured to allow patient entry of the pre-delivery pain estimate and the post-delivery pain estimate.3. The system of claim 2 , wherein the system is configured to prevent the controller from applying the treatment dose until the patient has ...

Подробнее
Номер записи: 81
20-06-2019 дата публикации

Privacy protection of images in online settings

Номер: US20190191300A1
Автор: Amos Cahan, Ruchi Mahindru, Syed Yousaf Shah, Valentina Salapura
Принадлежит: International Business Machines Corp

A system, method and program product for providing online privacy of image data. A centralized image privacy service is disclosed that includes: a user interface for allowing users to configure privacy profiles and provide profile images; an image scanning system that scans participating online sites for image data that matches the profile images; and a detection response system that determines a responsive action in response to a detected match based on an associated privacy profile, wherein the responsive action includes sending a masking request to the participating online site where the detected match occurred.

Подробнее
Номер записи: 82
21-07-2016 дата публикации

ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE

Номер: US20160206612A1
Автор: AL SHAREFFI Kadum A., COHEN Jonathan Marc, DIORIO Christopher Richard, EHRNSPERGER Eric C., MENG Xu, SHAH Syed M.
Принадлежит:

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. 1. A pharmaceutical composition for oral administration comprising a solid dosage of methylnaltrexone , or a pharmaceutically acceptable salt thereof , and an amphiphilic pharmaceutically acceptable excipient comprising (i) a saturated or unsaturated , branched or unbranched , cyclic or acyclic Caliphatic group that is optionally substituted and that has a pKa of 3 or less; or (ii) a saturated , unbranched , acyclic , unsubstituted Calkyl group; and wherein when the methylnaltrexone , or the pharmaceutically acceptable salt thereof , and the amphiphilic pharmaceutically acceptable excipient are in solution , the apparent octanol/water partition coefficient for methylnaltrexone is at least 0.25 at a pH between 1 and 4.2. The pharmaceutical composition of claim 1 , wherein the methylnaltrexone claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and the amphiphilic pharmaceutically acceptable excipient form an ion pair when dissolved in solution.3. The pharmaceutical composition of claim 2 , wherein the ion pair is formed when the methylnaltrexone claim 2 , or a pharmaceutically acceptable salt thereof and the amphiphilic pharmaceutically acceptable excipient are dissolved in solution at a pH of greater than about 1 and less than about 4.4. The pharmaceutical composition of claim 3 , further comprising a disintegrant.5. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable excipient comprises a sulfate (—OSO) group.6. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable excipient comprises an acyclic Caliphatic group that is optionally substituted.7. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable excipient comprises a saturated claim 1 , unbranched claim 1 , acyclic claim 1 ...

Подробнее
Номер записи: 83
05-08-2021 дата публикации

SYSTEMS AND METHODS FOR PRE-BOOT BIOS HEALING OF PLATFORM ISSUES FROM OPERATING SYSTEM STOP ERROR CODE CRASHES

Номер: US20210240561A1
Автор: Downum Steven A., Sayyed Ibrahim, SHAH Arifullah Syed
Принадлежит: DELL PRODUCTS L.P.

An information handling system may include a processor and a basic input/output system comprising a program of instructions executable by the processor and configured to cause the processor to determine if a captured stop error code captured in connection with an operating system stop error occurring during a previous boot session of the information exists on a memory accessible to the basic input/output system and responsive to the captured stop error code existing on the memory, read the captured stop error code and perform a remedial action based on the captured stop error code. 1. An information handling system comprising:a processor; and perform preboot healing of firmware to address stop error code crashes wherein the preboot healing of firmware includes;', 'determining if a captured stop error code captured in connection with an operating system stop error occurring during a previous boot session of the information handling system exists on a memory accessible to the basic input/output system; and', reading the captured stop error code; and', 'performing a remedial action based on the captured stop error code., 'responsive to the captured stop error code existing on the memory], 'a basic input/output system comprising a program of instructions executable by the processor and configured to cause the processor to2. The information handling system of claim 1 , wherein the preboot healing of firmware includes:responsive to no captured stop error code existing on the memory, allowing the information handling system to proceed to an operating system boot session; andin the event of an operating system stop error occurring during the operating system boot session, and in concert with an operating system of the information handling system, capturing a stop error code generated in connection with the operating system stop error and store the stop error code in the memory.3. The information handling system of claim 1 , wherein the remedial action comprises returning ...

Подробнее
Номер записи: 84
12-08-2021 дата публикации

System and method for quantifying qualitative patient-reported data sets

Номер: US20210244952A1
Автор: Matthew John IORIO, Nemath Syed Shah
Принадлежит: Neuros Medical Inc

Methods and apparatuses for collecting and quantifying patient-reported data from a neuromodulator. The patient-reported data typically includes a pain score that quantifies the level of pain experienced by the patient at a particular time. The apparatus can include a user interface that allows the patient to enter such information in real time. The methods and apparatuses can include a correlation process, whereby each patient-reported entry is correlated with a corresponding neuromodulation treatment. This correlation can be used to identify treatment parameters and dosages that are most effective, and to further identify when certain dosages are most effective. This information can further be used as feedback to generate optimized treatments for a specific patient and iteratively improve the treatments. In some cases, the correlation process identifies under reported or over reported data, which can be filtered out to provide more accurate optimized treatments.

Подробнее
Номер записи: 85
12-08-2021 дата публикации

LANE DETECTION AND DISTANCE ESTIMATION USING SINGLE-VIEW GEOMETRY

Номер: US20210248392A1
Автор: ALI Afsheen Rafaqat, ALI Ahmed, Hassan Ali, Kazmi Syed Wajahat Ali Shah, KHAN Hussam Ullah, ZAHEER Aamer
Принадлежит:

Disclosed are methods, devices, and computer-readable media for detecting lanes and objects in image frames of a monocular camera. In one embodiment, a method is disclosed comprising receiving a sample set of image frames; detecting a plurality of markers in the sample set of image frames using a convolutional neural network (CNN); fitting lines based on the plurality of markers; detecting a plurality of vanishing points based on the lines; identifying a best fitting horizon for the sample set of image frames via a RANSAC algorithm; computing an inverse perspective mapping (IPM) based on the best fitting horizon; and computing a lane width estimate based on the sample set of image frames using the IPM in a rectified view and the parallel line fitting. 1. A method comprising:receiving a sample set of image frames;detecting a plurality of markers in the sample set of image frames using a convolutional neural network (CNN);fitting lines based on the plurality of markers;detecting a plurality of vanishing points based on the lines;performing a random sample consensus (RANSAC) algorithm on the plurality of vanishing points to identify a best fitting horizon for the sample set of image frames;computing an inverse perspective mapping (IPM) based on the best fitting horizon; andcomputing a lane width estimate based on the sample set of image frames using the IPM in a rectified view and the line fitting.2. The method of claim 1 , wherein detecting a plurality of markers comprises detecting claim 1 , using a convolutional neural network (CNN) claim 1 , a plurality of markers situated along a lane boundary of a roadway included in the sample set of image frames.3. The method of claim 1 , wherein computing the IPM comprises computing a rectification homography based on an intrinsic matrix of a camera used to capture the sample set of image frames and a rotation matrix claim 1 , the rotation matrix calculated based on the best fitting horizon and a road plane normal.4. The ...

Подробнее
Номер записи: 86
23-10-2014 дата публикации

ENTERIC COATED MULTIPARTICULATE COMPOSITION WITH PROTEINACEOUS SUBCOAT

Номер: US20140314860A1
Автор: HASSAN FRED, Shah Syed
Принадлежит: ZX PHARMA LLC

A multiparticulate composition includes a plurality of individual enteric coated cores containing one or more terpene-based active ingredients and having a continuous proteinaceous subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings. The continuous proteinaceous subcoating layer prevents volatile terpene-based active ingredients from leaving the core, even when the core is heated during processing or stored for long periods above room temperature. The multiparticulate composition may be used to treat gastrointestinal disorders. 1. A multiparticulate composition comprising a plurality of individual spheroidal enteric coated cores having a diameter of about 0.1 mm to about 3 mm , said individual spheroidal enteric coated cores containing one or more terpene-based active ingredients and having a continuous gelatin film subcoating layer covering the individual cores and separating the individual cores from their respective enteric coatings.2. The multiparticulate composition of claim 1 , wherein the enteric coated cores further comprise a proton pump inhibitor.3. The multiparticulate composition of claim 1 , wherein the enteric coated cores further comprise an anti-inflammatory.4. The multiparticulate composition of claim 1 , wherein the enteric coated cores further comprise an immune suppressor.5. The multiparticulate composition of claim 1 , wherein the one or more terpene-based active ingredients include terpene-containing essential oils and/or L-menthol.6. The multiparticulate composition of claim 1 , wherein the one or more terpene-based active ingredients include peppermint oil and/or L-menthol.7. The multiparticulate composition of claim 1 , wherein the one or more terpene-based active ingredients include L-menthol and caraway oil.8. The multiparticulate composition of claim 1 , wherein the one or more terpene-based active ingredients include L-menthol and peppermint oil.9. The multiparticulate ...

Подробнее
Номер записи: 87
17-08-2017 дата публикации

Multiparticulate L-Carnitine And Nootropic Compositions And Related Methods

Номер: US20170231940A1
Автор: Diorio Christopher, HASSAN FRED, Hassan Noreen, SHAH Syed M.
Принадлежит: Physician's Seal, LLC

A composition includes a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates. The individual particulates respectively have: a core including an active ingredient combination of an L-carnitine and a nootropic substance and a release controlling polymer over the core that substantially prevents release of the active ingredients in stomach acid and permits release of the active ingredients in an intestinal pH environment. The composition may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body and/or cognitive impairment. 1. A composition comprising a therapeutically effective pharmaceutical dosage form including a plurality of individual particulates , the individual particulates respectively having:a core including an active ingredient combination of an L-carnitine and a nootropic substance; anda release controlling polymer over the core that substantially prevents release of the active ingredient combination in stomach acid and permits release of the active ingredient combination an intestinal pH environment.2. The composition of claim 1 , wherein the L-carnitine is within an interior solid portion of the core and the nootropic substance is within a coating over the interior solid portion of the core.3. The composition of claim 1 , wherein the core includes a solid interior portion and the L-carnitine and nootropic substance are in the solid interior portion of the core.4. The composition of claim 1 , wherein the L-carnitine is selected from at least one of L-carnitine claim 1 , acetyl L-carnitine claim 1 , and propionyl L-carnitine.5. The composition of claim 1 , wherein the nootropic substance is selected from at least one of L-serine and citicoline.6. The composition of claim 1 , wherein an average diameter of the individual particulates is 0.1 to 3 mm.7. The composition of claim 1 , wherein the therapeutically effective pharmaceutical dosage form includes 300 mg to 800 ...

Подробнее
Номер записи: 88
25-08-2016 дата публикации

Controlled-Release Compositions of Melatonin Combined with Sedative and/or Analgesic Ingredients

Номер: US20160243038A1
Автор: Diorio Christopher, HASSAN DANIEL, HASSAN FRED, SHAH Syed M.
Принадлежит:

Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients. 1. A composition comprising a pharmaceutical dosage form having:a solid core including a combination of melatonin and a GABA receptor agonist ingredient located together within a first acidified polymeric matrix;an expedited release portion including 5% to 50% of the GABA receptor agonist ingredient in the pharmaceutical dosage form, the expedited release portion being effective to release substantially all of the GABA receptor agonist ingredient therein within about 2 hours from placement in a 0.1 N HCl solution; anda sustained release portion including the remainder of the GABA receptor agonist ingredient in the pharmaceutical dosage form, the sustained release portion being effective to release substantially all of the GABA receptor agonist ingredient therein within about 10 hours from placement in a phosphate buffer with a pH of 6.8.2. The composition of claim 1 , wherein the first acidified polymeric matrix has a pH of about 1 to about 4.4.3. The composition of claim 1 , wherein the sustained release portion includes a plurality of individual granules that have the remainder of the GABA receptor agonist ingredient in the pharmaceutical dosage form therein.4. The composition of claim 1 , further comprising an analgesic ingredient in the expedited release portion.5. The composition of claim 1 , further comprising an analgesic ingredient in the expedited release portion; andwherein the sustained release portion includes a plurality of individual granules that have ...

Подробнее
Номер записи: 89
23-08-2018 дата публикации

APPARATUS, COMPUTER PROGRAM AND METHOD

Номер: US20180240119A1
Автор: Corbalan Marc, Dewar Michael, Divitt David, SHAH Syed Asim Ali, Stephens Jeremy
Принадлежит: IPCO 2012 Limited

An apparatus for identifying an end node bank account in a network of bank accounts for funds from a fraudulent transaction, comprising processing circuitry configured to: identify a node account into which funds from the fraudulent transaction are paid; determine the number of account relationships associated with the node account; and identify the node account as an end node bank account when the number of account relationships is above a threshold value. 1: An apparatus for identifying an end node bank account in a network of bank accounts for funds from a fraudulent transaction , the apparatus comprising: identify a node account into which funds from the fraudulent transaction are paid,', 'determine the number of account relationships associated with the node account, and', 'identify the node account as an end node bank account when the number of account relationships is above a threshold value., 'processing circuitry configured to'}2: The apparatus according to claim 1 , wherein the threshold value is 500.3: The apparatus according to claim 1 , wherein the funds are received at the node at a first time claim 1 , and wherein the processing circuitry is further configured todetermine that funds have been transferred from the node account at a second time, andidentify the node account as an end node bank account when the time difference between the first time and second time is above a threshold.4: An apparatus for identifying an end node bank account in a network of bank accounts for funds from a fraudulent transaction claim 1 , the apparatus comprising: identify a node account into which funds from the fraudulent transaction are paid at a first time,', 'determine that funds have been transferred from the node account at a second time, and', 'identify the node account as an end node bank account when the time difference between the first time and the second time is above a threshold., 'processing circuitry configured to'}5: The apparatus according to claim 4 , ...

Подробнее
Номер записи: 90
23-07-2020 дата публикации

Solid Micronized Melatonin Composition

Номер: US20200230059A1
Автор: HASSAN DANIEL, SHAH Syed M.
Принадлежит:

A melatonin composition has a dry granulation including a melatonin powder with a median melatonin particle size of 5 μm to 40 μm, a carboxylic acid powder, and a powder of a hydrogel-forming polymer. The dry granulation is combined with pharmaceutical excipients in a dry orally ingestible pharmaceutical dosage form adapted to absorb water upon ingestion and form a hydrogel including soluble melatonin and soluble carboxylic acid in the hydrogel, the carboxylic acid being in an amount sufficient to impart a pH of 4.4 or less to the hydrogel after ingestion. 1. A method of making a melatonin dosage form , the method comprising:forming granules by dry granulating a melatonin powder having a median melatonin particle size of 5 μm to 40 μm, a carboxylic acid powder, and a powder of a hydrogel-forming polymer to form a dry granulation having a substantially uniform distribution of melatonin powder, carboxylic acid powder, and powder of the hydrogel-forming polymer; andplacing the granules into a dry orally ingestible pharmaceutical dosage form, the dosage form being adapted to absorb water upon ingestion and form a hydrogel including soluble melatonin and soluble carboxylic acid in the hydrogel, the carboxylic acid being in an amount sufficient to impart a pH of 4.4 or less to the hydrogel after ingestion.2. The method of claim 1 , wherein dry granulating is performed without including a liquid solvent.3. The method of claim 1 , wherein the dosage form is selected from a tablet claim 1 , capsule claim 1 , caplet claim 1 , and multiparticulate.4. The method of claim 1 , wherein the carboxylic acid is citric acid.5. The method of claim 1 , wherein a particle size of the carboxylic acid is greater than the particle size of the melatonin.6. The method of claim 1 , further comprising compacting the granules by roller compaction and/or slugging after the forming step and prior to the placing step.7. The method of claim 1 , wherein the dosage form comprises 0.4% w/w to 8% w/w ...

Подробнее
Номер записи: 91
31-08-2017 дата публикации

NERVE CUFF ELECTRODE FOR NEUROMODULATION IN LARGE HUMAN NERVE TRUNKS

Номер: US20170246453A1
Автор: Fang Zi-Ping, Shah Nemath Syed
Принадлежит:

A durable nerve cuff electrode for achieving block of an action potential in a large diameter nerve. 1. A nerve cuff electrode comprisinga plurality of conductive nerve contact segments, the segments having an inner surface contacting a nerve trunk and an outer surface not contacting the nerve trunk;at least a single wire of a conductive biocompatible material operatively connecting the plurality of conductive nerve contact segments thus forming a segmented strip, the wire configured as helical portions separated by non-helical portions where the non-helical portions are secured to the surface of the conductive nerve contact segments not contacting the nerve trunk; anda conductive lead capable of operatively connecting a waveform generator to at least one of the plurality of nerve contact segments.2. The electrode of where the wire helical portions are along the wire length between the conductive nerve contact segments.3. The electrode of where the wire non-helical portions are secured to the conductive nerve contact segments by a plurality of spot welds.4. The electrode of where the wire helical portions are embedded in a non-conductive material.5. The electrode of where the wire non-helical portion connects the conductive nerve contact segments.6. The electrode of further comprising a second wire operatively connecting the plurality of nerve contact segments claim 1 , the second wire generally parallel with the first wire.7. The electrode of where the conductive nerve contact segments are platinum.8. The electrode of where the wires are stainless steel.9. The electrode of where the non-conductive material is silicone.10. A nerve cuff electrode comprising:a plurality of platinum nerve contact segments, each nerve contact segment comprising an inner surface contacting a nerve trunk and an outer surface not contacting the nerve trunk;at least two wires of a conductive biocompatible material operatively connecting the plurality of platinum nerve contact segments thus ...

Подробнее
Номер записи: 92
20-11-2014 дата публикации

Low-Complexity, Adaptive, Fractionally Spaced Equalizer with Non-Integer Sampling

Номер: US20140341267A1
Автор: Ali Shah Syed Faisal, Li Chuandong, Zhang Zhuhong
Принадлежит: Futurewei Technologies, Inc.

An apparatus comprising a memory and a processor coupled to the memory, wherein the memory includes instructions that when executed by the processor cause the apparatus to perform the following receive an incoming signal at a sampling rate that is greater than a symbol rate associated with the incoming signal, replicate a plurality of data streams from the incoming signal, apply a plurality of fractional delays for the data streams, and perform an adaptive equalization on a plurality of data blocks generated from the data streams, wherein the fractional delay is applied to the data streams independently of the adaptive equalization, and wherein the adaptive equalization implements taps spaced at a fraction of a symbol interval associated with the incoming signal. 1. An apparatus comprising:a memory; and receive an incoming signal at a sampling rate that is greater than a symbol rate associated with the incoming signal;', 'replicate a plurality of data streams from the incoming signal;', 'apply a plurality of fractional delays for the data streams; and', 'perform an adaptive equalization on a plurality of data blocks generated from the data streams,, 'a processor coupled to the memory, wherein the memory includes instructions that when executed by the processor cause the apparatus to perform the followingwherein the fractional delay is applied to the data streams independently of the adaptive equalization, andwherein the adaptive equalization implements taps spaced at a fraction of a symbol interval associated with the incoming signal.2. The apparatus of claim 1 , wherein the sampling rate of the incoming signal is less than two times the symbol rate.3. The apparatus of claim 1 , wherein the sampling rate is equal to α/T claim 1 , wherein α is a rational number that has a range that is greater than one and less than two claim 1 , and wherein T represents the symbol interval for the incoming signal.4. The apparatus of claim 3 , wherein α is equal to N/M claim 3 , ...

Подробнее
Номер записи: 93
07-09-2017 дата публикации

Fractionally Spaced Adaptive Equalizer With Non-Integer Sampling

Номер: US20170257234A1
Автор: Ali Shah Syed Faisal, Li Chuandong, Zhang Zhuhong
Принадлежит:

An apparatus for performing fractionally spaced adaptive equalization with non-integer sub-symbol sampling has an adaptive equalizer that receives a continuous stream of input data having a non-integer, fractional delay between consecutive samples at a non-integer, sub-symbol rate and outputs a stream of equalized data based on tap weights of taps of the adaptive equalizer that are spaced at an interval corresponding to the non-integer, sub-symbol rate. The tap weights are updated independently of the fractional delay between consecutive samples of the input data using an error signal. An equalizer output alignment component downstream of the adaptive equalizer aligns the stream of equalized data with a corresponding transmitted symbol. 1. An apparatus for performing fractionally spaced adaptive equalization based on non-integer sub-symbol sampling , the apparatus comprising:an adaptive equalizer configured to receive a continuous stream of input data having a non-integer, fractional delay between consecutive samples at a non-integer, sub-symbol rate and to output a stream of equalized data based on tap weights of the adaptive equalizer, wherein the adaptive equalizer comprises a plurality of taps and a tap weight update component for updating the tap weights using an error signal; andan equalizer output alignment component disposed downstream of the adaptive equalizer and comprising a fractional delay filter (FDF) for aligning the stream of equalized data with a corresponding transmitted symbol,wherein the taps are spaced at an interval corresponding to the non-integer, sub-symbol rate, andwherein the tap weights are updated independently of the fractional delay between consecutive samples of the input data.2. The apparatus of claim 1 , wherein the equalizer output alignment component further comprises a serial-to-parallel (S/P) converter claim 1 , wherein the S/P converter is configured to receive the stream of equalized data from the adaptive equalizer and to ...

Подробнее
Номер записи: 94
07-09-2017 дата публикации

ROLE-SPECIFIC SERVICE CUSTOMIZATION

Номер: US20170257373A1
Автор: Furtado Andre Wilson Brotto, Richardson Matthew, Rounthwaite Robert L., Shah Syed Fahad Allam, Sharma Shantanu, Shi Xiaohan, White Ryen
Принадлежит:

In many computing scenarios, an individual may choose to interact with a service in a variety of roles, and may therefore create a set of accounts respectively representing the service. However, the use of multiple accounts by the same individual may introduce considerable administrative complications (e.g., failing to update all accounts with new information results in stale and/or conflicting account information), and may reduce the efficiency and/or scalability of the service. Presented herein are techniques for enabling individuals to interact with services through various roles. Such techniques involve evaluating the individual's role determinants to identify and automatically select the individual's current role; selecting a current role profile, as a subset of the details of the individual profile that are associated with the current role, and excluding details that are not associated with the current role; and performing the service according to the current role profile of the individual. 1. A server that provides a service to an individual represented by an individual profile , the server comprising:a processor; and a current role selector that, responsive to detecting a role determinant of the individual, selects, among at least two roles of the individual, a current role that is associated with the role determinant;', 'a role profile selector that selects, from the individual profile, a current role profile comprising at least one selected individual profile detail that is associated with the current role, and excluding at least one excluded individual profile detail that is not associated with the current role; and', 'a service provider that provides the service to the individual according to the current role profile of the individual., 'a memory storing instructions that, when executed by the processor, provide2. The server of claim 1 , wherein the service provider provides the service to the individual by describing the individual to a second ...

Подробнее
Номер записи: 95
04-12-2014 дата публикации

Enteric Coated Multiparticulate Controlled Release Peppermint Oil Composition and Related Methods

Номер: US20140356440A1
Автор: HASSAN DANIEL, HASSAN FRED, SHAH Syed M.
Принадлежит: ZX PHARMA, LLC

A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders. 1. A composition providing controlled-release of peppermint oil , the composition comprising a plurality of enteric coated solid spheroidal cores , the cores comprising peppermint oil , microcrystalline cellulose , and a hydrophilic binder , the cores having a diameter of about 0.1 to about 3 mm.2. The composition of claim 1 , wherein the cores are spheroidal and have a diameter of about 1 mm to about 2.5 mm.3. The composition of claim 1 , wherein the cores are spheroidal and have a diameter of is less than about 1.4 mm.4. The composition of claim 1 , wherein the cores release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HCl solution and claim 1 , subsequently no less than about 85% of the peppermint oil within about eight hours of being placed in a substantially neutral pH environment.5. The composition of claim 1 , wherein the cores release no more than about 20% of the peppermint oil within about two hours of being placed in a 0.1 N HCl solution and claim 1 , subsequently no less than about 60% of the peppermint oil within about two hours of being placed in a substantially neutral pH environment.6. The composition of claim 1 , wherein the peppermint oil in the cores is present in combination with at least one terpene-based substance selected from L-menthol claim 1 , caraway oil claim 1 , orange oil claim 1 , ginger oil claim 1 , turmeric oil claim 1 , curcumin oil claim 1 , and fennel oil.7. The composition of claim 1 , wherein the peppermint oil in the cores is present in combination with more L-menthol than provided by the peppermint oil itself.8. The ...

Подробнее
Номер записи: 96
21-09-2017 дата публикации

Multiparticulate L-Menthol Formulations and Related Methods

Номер: US20170266125A1
Автор: HASSAN DANIEL, HASSAN FRED, HASSAN SARAH, SHAH Syed M.
Принадлежит:

A pharmaceutical dosage form includes an effective amount of L-menthol for treating a gastrointestinal disorder. The L-menthol is within a plurality of particulates having a core including crystalline L-menthol dissolved in a terpene-based essential oil. A proteinaceous coating of a continuous film of proteinaceous material is over the core.

Подробнее
Номер записи: 97
21-09-2017 дата публикации

TIGECYCLINE COMPOSITIONS AND METHODS OF PREPARATION

Номер: US20170266290A1
Автор: Fawzi Mahdi B., SHAH Syed M., Zhu Tianmin
Принадлежит: WYETH LLC

The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.

Подробнее
Номер записи: 98
13-08-2020 дата публикации

Multiparticulate L-Carnitine Compositions and Related Methods

Номер: US20200253882A1
Автор: Hassan Noreen, SHAH Syed M.
Принадлежит:

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain a solid core containing the L-carnitine, and an enteric coating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body. 1. An oral controlled-release multiparticulate dosage form comprising an L-carnitine carried on a plurality of individually enteric coated particulates that independently disperse in a person's stomach after oral ingestion and travel through the stomach and past a pyloric sphincter without substantially releasing the L-carnitine in the stomach , the individually enteric coated particulates comprising (a) a solid core including the L-carnitine and (b) an enteric coating over the solid core , a predominant component of the enteric coating being an enteric polymer.2. The dosage form of claim 1 , wherein the L-carnitine is selected from at least one of L-carnitine claim 1 , acetyl-L-carnitine claim 1 , and propionyl-L-carnitine.3. The dosage form of claim 1 , wherein the enteric polymer is selected from at least one of methacrylic acid co-polymer claim 1 , cellulose acetate phthalate claim 1 , and polyvinyl acetate phthalate.4. The dosage form of claim 1 , wherein the solid core comprises a pellet and the L-carnitine is located on an outer surface of the pellet.5. The dosage form of claim 4 , wherein the pellet is a non-pareil or microcrystalline cellulose pellet.6. The dosage form of claim 1 , wherein the L-carnitine is blended with microcrystalline cellulose and hydroxypropyl methylcellulose in the solid core.7. The dosage form of claim 1 , wherein an average diameter of the individually enteric coated ...

Подробнее
Номер записи: 99
18-12-2014 дата публикации

Multiparticulate L-Carnitine Compositions and Related Methods

Номер: US20140370112A1
Автор: Hassan Noreen, SHAH Syed M.
Принадлежит:

An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body. 1. An oral controlled-release multiparticulate dosage form comprising a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach , the individual particulates comprising (a) a solid core containing the L-carnitine , (b) a subcoating containing a cellulosic water soluble polymer over the core , and (c) an enteric coating over the subcoating.2. The dosage form of claim 1 , wherein the L-carnitine is selected from at least one of L-carnitine claim 1 , acetyl-L-carnitine claim 1 , and propionyl-L-carnitine.3. The dosage form of claim 1 , wherein the enteric coat is selected from at least one of methacrylic acid co-polymer claim 1 , cellulose acetate phthalate claim 1 , and polyvinyl acetate phthalate.4. The dosage form of claim 1 , wherein the solid core comprises a pellet and the L-carnitine is located on an outer surface of the pellet.5. The dosage form of claim 4 , wherein the pellet is a non-pareil or microcrystalline cellulose pellet.6. The dosage form of claim 1 , wherein the L-carnitine is blended with microcrystalline cellulose and hydroxypropyl methylcellulose in the solid core.7. The ...

Подробнее
Номер записи: 100